リウマチ病セミナー　XX

出版社： 永井書店
著者：
発行日： 2009-12-10
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784815918545
シリーズ： リウマチ病セミナー
電子書籍版： 2009-12-10 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,020 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

新しい知見に基づく新しい考え方が随所に出てきて、それらがリウマチ病の捉え方に大きく影響している。考え方や知見、技術、治療薬剤の開発など、そらに骨粗鬆症あるいは慢性病との取り組み方、RAの死亡率の追跡などなど各方面から出揃ってきている。

目次

  • リウマチ病セミナー　XX

    ―目次―

    炎症リウマチ
    　Myositisとウイルス
    　ベーチェット病2008
    　Fibroblastic Rheumatism
    　早期関節リウマチおよび早期分類不能関節炎の予後について
    　RAの死亡率と死亡要因の変遷
    　Neutrophilic Dermatosis

    骨関節、脊椎、神経
    　脊椎神経分布と神経原性炎症
    　偽痛風
    　histiocytosis再訪
    　野球肩
    　梨状筋症候群　再考

    燐・カルシウム代謝
    　糖尿病と骨粗鬆症

    検査法
    　リウマチ手関節の手根配列異常に対する3次元的定量評価

    生物学的反応
    　インフラマゾームと自己炎症症候群
    　Wnt pathway
    　過労の生体反応と病気
    　リウマチ性疾患とホモシステイン
    　リウマチ病と非線形思考

    治療と副作用
    　関節破壊機序と転写因子 c-Fos/AP-1阻害薬
    　骨再生医療の現状
    　生物学的製剤 Up-date
    　ほか

    手術
    　関節リウマチ患者の手関節変化―手術症例についての調査―
    　腱板の断裂と修復2008：Double Anchor Footprint Fixation
    (DAFF)法を用いた鏡視下腱板修復術―
    　腰部脊柱管狭窄症の手術
    　人工椎間板再訪

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.5 掲載の参考文献
1) 川合 充. 筋炎の基礎知識・分類と定義. CLINICAL NEUROSCIENCE 2004;22:1129-1131.
 
2) 富永謙太郎. PolymyositisとVirus. リウマチ病セミナーI (七川歡次監修). 1990, p71-81, 大阪, 永井書店.
 
3) 前田恵治. 原発性炎症性筋疾患2003. リウマチ病セミナーXV (七川歡次監修). 2004, p1-10, 大阪, 永井書店.
 
4) 中村道三, 橋本修二. 炎症性ミオパチー・インフルエンザウイルス. 別冊日本臨床2001;35:167-170.
 
5) Servidei S, Miranda AF, Gamboa ET. Infectivity of influenza B virus in cultured human muscle. Acta Neuropathol 1987;73:67-76.
PubMed
6) Gamboa ET, Eastwood AB, Hays AP, et al. Isolation of influenza virus from muscle in myoglobinuric polymyositis. Neurology 1979;29:1323-1335.
PubMed
7) Kessler HA, Trenholme GM, Harris AA, et al. Acute myopathy associated with influenza A/Texas/1/77infection. Isolation of virus from a muscle biopsy specimen. JAMA 1980:243:461-462.
PubMed
8) 猪瀬 優, 樋口逸郎. 炎症性ミオパチー・その他のウイルス. 別冊日本臨床2001;35:174-177.
 
9) Greco TP, Askenase PW, Kashgarian M. Postviral myositis:myxovirus-like structures in affected muscle. Ann Intern. Med 1977;86:193-194.
PubMed
10) Chou SM. Inclusion body myositis:a chronic persistent mumps myositis? Hum Pathol 1986;17:765-777.
PubMed
11) Cupler EJ, Leon-Monzon M, Miller J, et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-1893.
PubMed
12) Dalakas MC, Rakocevic G, Shatunov A, et al. Inclusion body myositis with human immunodeficiency virus infection:four cases with clonal expansion of viral-specific T cells. Ann Neurol 2007; 61:466-475.
PubMed
13) Ozden S, Gessain A, Gout O, et al. Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy. Clin Infect Dis 2001;32:510-514.
 
14) Dalakas MC Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-447.
PubMed
P.10 掲載の参考文献
1) Behget H. Uber residivietende apththose, durch ein virus verursachte geschwura am mund, am auge und an den genitalien. Dermatol Wochenschr 1937;105:1152-1157.
 
2) Sakane T, Takeno T. Novel approaches to Behcet's disease. Exp Opin Invest Drugs 2000;9:1993-2005.
 
3) Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease. Int Rev Immunol 1997;14:21-32.
PubMed
4) Kaneko F, Oyama N, Yanagihori H, et al. The role of streptococcal hypersensitivity in the pathogenesis of Behcet's Disease. Eur J Dermatol 2008;18:489-498.
PubMed
5) Touitou I, Magne X, Molinari N, et al. MEFV mutations in Behcet's disease. Hum Mutat 2000;16:271-272.
PubMed
6) Imizalioglu N, Dursun A, Tastan B, et al. MEFV gene is a probable susceptibility gene for Behcet's disease. Scand J Rheumatol 2005;34:56-58.
 
7) Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet'ss disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003;21:S35-37.
 
8) Rabinovich E, Shinar Y, Leiba M, et al. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007:36:48-52.
PubMed
9) Naka K, Kurosawa S, Chiba S, et al. Involvement of innate immunity in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol 2008;152:245-251.
 
10) Mendes D, Correia M, Barbedo M, et al. Behcet's disease-a contemporary review. J Autoimmun 2009; 32:178-188.
PubMed
11) Kotter I, Gunaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behcet's disease under cyclosporin A (CSA) than under other rnedications-result of a retrospective analysis of 117 cases. Clin Rheumatol 2006:25:482-486.
PubMed
12) Akman-Demir G, Avranci O, Kurtuncu M, et al. Cyclosporine for Behcet's uveitis:is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 2008;26:S84-90.
 
13) Curnow SJ, Pryce K, Modi N, et al. Serum cytokine profiles in Behcet's disease:Is there a role for IL-15 in pathogenesis? Immunology Letters 2008:121:7-12.
 
14) International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-1080.
 
15) 塩沢和子. ベーチェット病2001. リウマチ病セミナーXIII (七川歡次監修). 2002, p9-26, 大阪, 永井書店.
 
16) Fresko I, Yazici H. Treatment strategies for Behcet's disease. Expert opin Pharmacother 2008;9:3211-3219.
 
17) Kotter I, Eckstein AK, Stubiger N, et al. The use of interferon α in Behcet's disease:review of literature. Semin Arthritis Rheum 2004;33:320-335.
 
18) Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet's disease:report of a task force of the European Standing Committee for International Studies Including Therapeutics (ESCIST). Ann Rheum Dis 2008;Jan 31.
 
19) Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology 2007;46:736-741.
PubMed
20) Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease:a double blind, placebo controlled study. J Rheumatol 2005;32:98-105.
PubMed
21) van Laar JA, Missotten T, van Daele PL, et al. Adalimumab:a new modality for Behcet's disease. Ann Rheum Dis 2007;66:565-566.
PubMed
22) Mushtaq B, Saeed T, Situnayake RD, et al. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 2007;21:824-825.
PubMed
23) Botsios C, Sfriso P, Furlan A, et al. Resistant Behcet's disease responsive to anakinra. Ann Intern Med 2008;149:284-286.
PubMed
24) Borhani Haghighi A, Safari A. Tocilizumab may be a potential addition to our weapons against neuro-Behcet's disease. Med Hypotheses 2008;71:156-157
 
P.20 掲載の参考文献
1) Chaouat Y, Aron-Brunetiere R, Faures B, et al. Une nouvelle entite:le rhumatisme fibroblastique. Apropos d'une observation. Rev Rhum 1980;47:345-351.
 
2) Rety F, Tayebjee OA, Servettaz A, et al. Radiological bone lesions in fibroblastic rheumatism; case report. Press Med 2007;36:432-436.
 
3) Watanabe S, Kamada K, Imai H, et al. A case of fibroblastic rheumatism:Clinical, radiological, and histological features. Modern Rheumatology 2009 (in print)
 
4) 七川歡次:Fibroblastic rheumatism (線維芽細胞性リウマチ) とリウマチ病でのfibrosis. リウマチ病セミナーV (七川歡次監修). 1994, p58-65, 大阪, 永井書店.
 
5) Crouzet J, Amouroux J, Duterque M, et al. Rhumatisme fibroblastique:Un cas avec etude de l'histologie synoviale. Rev Rheum 1982;49:469-472.
 
6) Taccari E, Teodori S, Zoppini A. Le rhumatisme fibroblastique du sujet age. Donnees histopathologiques, ultrastructurales et problemes de diagnostic differentiel. Rev Rhum 1987;54:463-467.
PubMed
7) Chaouat Y, Binet O, Faures-Quenet B, et al. Le rhumatisme fibroblastique. Une entity clinique et histologique. Rev Rhum 1988;55:59-62.
PubMed
8) Hernandez RJ, Headington JT, Kaufman RA. Case report 511. Skeletal Radiol 1989;8:43-45.
 
9) Levigne V, Perrot L, Faisant M, et al. Rhumatisme fibroblastique. Ann Dermatol Venereol 1990:117:199-202.
 
10) Barbaud A, Schmutz JL, Chemidling M, et al. Le rhumatisme fibroblastique. Ann Dermatol Venereol 1990;117:828-830.
 
11) Leclech C, Croue A, Masson C, et al. Rhumatisme fibroblastique. Ann Dermatol Venereol 1990; 117:830-833.
PubMed
12) Lacour J, Maquart FX, Bellon G, et al. Fibroblastic rheumatism:Clinical, histological, immunohistological, ultrastructural and biochemical study of a case. Br J Dermatol 1993;128:194-202.
PubMed
13) Ostlere LS, Stevens HP, Jarmulowicz M, et al. Fibroblastic rheumatism. Clin Exp Derm 1994;19:268-270,
 
14) Kanzler MH, Dhillon I, Headington JT. Fibroblastic rheumatism. Arch Dermatol 1995;131:710-712.
PubMed
15) Vittecoq O, Mejjad O, Da Silva F, et al. Preliminary experience with low-dose methotrexate in Fibroblastic rheumatism. Arthritis Rheum 1996;39:2070-2073.
PubMed
16) Romas E, Finlay M, Woodruff T. The arthropathy of fibroblastic rheumatism. Arthritis Rheum 1997; 40:183-187.
PubMed
17) Fam AG, Hanna W, Mak V, et al. Fibroblastic rheumatism:Clinical and histologic evolution of cutaneous manifestations. J Rheumatol 1998:25:2261-2266.
PubMed
18) Chkirate B, Job-Deslandre C. Rhumatisme fibroblastique:a propos d'un cas. Arch Pediatr 2001;8:389-392.
PubMed
19) Colonna L, Barbieri C, Di Lella G, et al. Fibroblastic rheumatism:A case without rheumatological symptoms. Acta Derm Venereol 2002:82:200-203.
PubMed
20) Lee JM Sundel RP, Liang MG. Fibroblastic rheumatism:Case report and Review of the literature. Ped Dermatol 2002:19:532-535.
 
21) Pedersen JK, Poulsen T, Petersen KH. Fibroblastic rheumatism:a Scandinavian case report. Ann Rheum Dis 2005;64:156-157.
 
P.28 掲載の参考文献
1) Machold KP, Eberl G, Leeb BF, et al. Early arthritis therapy:Rationale and current approrch J Rheumatol 1998;25 (suppl 55):13-19.
 
2) Qinn MA, Emery P. Window of opportunity in early rheumatoid arthritis:Possibility of altering the disease process with early intervation. Clin Exp Rheumatol 2003;21 (Suppl 31):S154-157.
 
3) O!Dell JR. Treating rheumatoid arthritis early:A window of opportunity?:Arthritis Rheum 2002; 46:283-285.
 
4) Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis:Arthritis Rheum 2003;48;1771-1774.
PubMed
5) Furst DE. Window of opportunity. J Rheumatol 2004;31:1677-1679.
PubMed
6) Aletaha D, Eberl G, Nell VPK, et al. Attitudes to early rheumatoid arthritis changing patterns. results of a survey. Ann Rheuma Dis 2004:63;1269-1275.
 
7) Amjadi-Begvand S, Khanna D, Park GS, et al. Daiting the"window of therapeutic opportunity"in early rheumatoid arthritis:Accuracy of patient recall of arthritis symptom onset. J Rheumatol 2004;31:1686-1692.
 
8) Korpela M, Lassonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying anti-rheumatc drugs:Arthritis Rheum 2004;50:2072-2081.
 
9) Huizinga TWJ, Landewe RBM. Early aggressive therapy in rheumatoid arthritis:a window of opportunity? Rheumatol 2005;1:2-3.
PubMed
10) Cush JJ. Early rheumatoid arthritis-is there a window of opportunity? JRheumatol 2007;34:(Suppl 80):1-7.
 
11) 福田孝昭. TNF阻害剤の臨床-わが国における臨床成績を中心に-TNF阻害療法における留意点-Window of opportunity. Nippon Rinsho 2007;65:1276-1281.
 
12) Machold KP, Stamm TA, Eberl GJM, et al. Very recent onset arthritis-Clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002;29:2278-2289.
 
13) Machold KP, Stamm TA, Nell VPK, et al. Very recent onset rheumatoid arthritis:clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatolgy 2007:46:342-349.
 
14) Raza K, Buckley CE, Salmon M, et al. Treating Very early rheumatoid arthritis. Best Practice Clin Rheumatol 2006;20:849-863.
 
15) Arndtt RC, et al. The American Rheumatism Association 1987 revised criteria classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
 
16) 松原 司, ら. 厚生省早期関節リウマチ診断基準. 厚生省リウマチ調査研究事業研究報告書1992:12.
 
17) 松原 司, 江口勝美, 三森経世. 関節リウマチ早期診断予測基準. 診断と治療:2008;96:369-376.
 
18) Banal F, Dougados M, Combescure C, et al. Sensitivity and specificity of the American college of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration:a systematic literature review and meta-analysis. Ann Rheum dis 2008;28:
 
19) Harrison BJ, Symmons DPH, Barret EM, et al. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 1998:25:2324-2330.
 
20) Visser H, Cessie SL, Vos K, et al. How to diagnosie rheumatoid arthritis early a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-365.
 
21) van der Helm-van Mil AHM, Cessie SL, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis-How to guide individual treatment decisions. Arthritis Rheum 2007;56:433-440.
 
22) Miedany YEL, Youssef S, Mehanna AN, et al. Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. J Bone Spine 2008;75:155-162.
 
23) Knudsen IS, Klalund M, Skjodt H, et al. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. relationship to disease activity and radiographic outcome. J Rheumatol 2008:35:1277-1287.
 
24) Quinn MA, Green MJ, Marzo-Ortega H, et al. Prognostic factors in large coort of patients with early undifferenciated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 2003;48:3039-3045.
 
25) Castoro-Rueda H, Kavanaugh A. Biologic therapy for early rheumatoid arthritis:the latest evidence. Cur Opin Rheumatol 2008;20:314-319.
 
26) van Aken, J, van Dongen H, Cessie S, et al. Comparison of long term-outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis:an observational cohort study. Ann Rheum Dis 2006, 65:20-25.
PubMed
27) Pinals RS, Masi MT, Larsen RA, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-1315.
 
28) Wolfe F, Ross K, Hawley DJ, et al. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic.:a study 1141 patients. J Rheumatol 1993;20:2005-2009.
 
29) Saarez-Almszor ME, Soskolne CL, Saunder LD, et al. Outcome in rheumatoid arthritis;A 1985 inception cohort study, J Rheumatol 1994:21:1438-1446.
 
30) Mottonen T, Paimela L, Ahonen J, et al. Outcome in patients with early rheumatoid arthritis treated according the"sawtooth"strategy. Arthritis Rheum 1996;39:996-1005.
PubMed
31) Harrison BJ, Symmons DP, Brennan P, et al. Natural remission in inflammatory polyarthritis:issue of definition and prediction. Br J Rheumatol 1996:35:1096-1100.
PubMed
32) Prevoo MI, van Gestel AM, van t Hof MA, et al. Remission in a prospective study of patient with rheumatoid arthritis. American Rheumatism Association preliminary remisson criteria in relation in the disease activity score. Br J Rheumatol 1996;35:1101-1105.
 
33) Nissila M, Ismaki H, Kaarela K, et al. Prognosis of inflammatory joint disease.:A three-year follow-up study. Scand J Rheumatol 1983;12:33-38.
 
34) Young A, Dixey J, Cox N, et al. How dose functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Result of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatolgy Oxford 2000;39:603-6141.
 
35) Lindqvist E, Saxne T, Gwborek P, et al. Ten year outcome in a cohort of patients with early rheumatoid arthritis:health status, diseaes process, and damage. Ann Rheum Dis 2002;61:1055-1059.
 
36) Jantti J, Kaarela K, Kautiainen H, et al. Radiographic remission in seropositive rheumatoid arthritis. A 20 year follow-up study. Clin Exp Rheumatol 2001;19:573-576.
 
37) Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modyfying anti-rheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002:46:894-898.
PubMed
38) Sokka T, Pincus T. Most patients receiving routins care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical criteria or American College of Rheumatolgy criteria for remission. J Rheumatol 2003;30:1138-1146.
PubMed
39) Balsa A, Larmon L, Gonzalez-Alvoio L. Value of disease activity Score 28 (DAS28) and DAS 28-3 compaired to American College of Rheumatolgy-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40-46.
 
40) Molenaar WT, Voskuyl AT, Dinant HJ, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004:50:36-42.
 
41) Ma"kinen H, Kautiainen H, Hannonen P, et al. Frequency of remission in early rheumatoid arthritis defined by 3 sets of critera.:A 5-year followup study. J Rheumatol 2005:32:796-800.
 
42) 村田紀和. 関節リウマチの寛解. リウマチ病セミナーXVIII (七川歡次監修). 2007, p33-39, 大阪, 永井書店.
 
43) Naz SM, Farragher TM, Bunn DK, et al. The influence o age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008; 58:985-989.
 
44) Visser H, Cessie S, Vos K, et al. How to diagnosis rheumatoid arthritis early;A prediction model for persistent' (erosive) arthritis. Arthritis Rheum 2002;46:357-365.
 
45) Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-243.
PubMed
46) Bang H, Egerer K, Gauliard A, et al. Mutasion and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-2511.
PubMed
47) Hayem G, Chazerain P, Combe B, et al. Anti-Sa antibody is accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999;26:7-13.
PubMed
48) El-Gabalaway HS, Wilkins JA. Anti-Sa antibodies:prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther 2004:6:86-89.
 
49) Vossenaar EK, Despres N, Lapoite R, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:142-150.
 
50) Boire G, Cossette P, Brum-Ferrnandes A, et al. Anti-Sa antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with resent-onset polyarthritis. Arthritis Res Ther 2005;7:592-603.
 
51) Dejaco C, Klotz W, Larcher H, et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8:1-6.
PubMed
52) Bongartz, T, Cantaert T, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology 2007;46:70-75.
PubMed
53) Burkhardt H, Sehnert B, Bockermann R, et al. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis.. Eur J Immunol 2005;35:1643-1652.
PubMed
54) Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alfa-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:1421-1429.
 
55) Syversen S, Goll GL, Haavardsholm EA, et al. A hig serum level of eotaxin (CCL 1 1) is associated with less radiographic progression in early rheumatoid arthritis patients. Arthritis Res Ther 2008:10:1-457.
 
56) Bresnihan B. Are synovial biopsies of diagnostic value?. Arthritis Res Ther 2003;5:271-278.
PubMed
57) McGonagle D, Pease C, Marzo-Ortega H, et al. Comparison of extracapsular change by magnetic resonance in imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol 2001;28:1825-1836.
 
58) Angwin J, Heald G, Lloyd A, et al. Reliability and sensitivity of joint space measurements in hand radiographics using computerized image analysis. J Rheumatol 2001;28:1837-1840.
 
59) 前田 晃. 画像診断とスコアリング. リウマチ病セミナーXVIII (七川歡次監修). 2007, p 140-152, 大阪, 永井書店.
 
60) Wakefield RJ, O!Connor PJ, Conaghan PG, et al. Finger tendon disease in untreated rheumatoid arthritis:A comparison of ultrasound and magnetic resonance imaging. Arthritis Rheum 2007;57:1158-1164.
PubMed
61) Bresnihan B. Are synovial biopsies of diagnostic value?. Arthritis Res Ther 2003;5:271-278.
PubMed
62) Huizinga TWJ, Amos CI, van der Helm-von Mil AHM, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRBI shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-3438.
 
63) Klareskog L, Padyukov L, Ronnelid J, et al. Genes, environment and immunity in development of rheumatioid arthritis. Curr Opin Rheumatol 2006;18:650-655.
 
64) van der Helm-van Mil AHM, Verpoort KN, Cessie SL, et al. The HLA-DRBI shared epitope alleles differ in the interaction with smoking predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007:56:425-432.
 
65) Alvarez I, Cooado J, Daura X, et al. The rheumatoid arthritis-assccioated allele HLA-DR10 (DRBI*1001) shares part of its repertoire with HLA-DR1 (DRB10101) and HLA-DR4 (DRB*0401) Arthritis Rheum 2008;58:1630-1639.
 
66) Goeb V, Dieude P, Daveau R, et al. Contribution of PTPN22 1858T, TNFR11 196R and HLA-sharede epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis. Rheumatology 2008;47:1208-1212.
PubMed
67) Fathi MA, Ezz-Eiden AM, Mosaz E, et al. Diagnostic performance and predictive value of rheumatoid factor, anti-cyclic-itrullinated peptide antibodies and HLA-DEB1 locus enes in rheumatoid arthritis. Int Arch Med 2008; 22:20.
 
68) de Vries RR, Huizinga TW, Toes RE. Redefinig the HLA and RA association:to be or not to be anti-CCP positive. J Autoimmun 2005;25 (Suppl):21-25.
 
69) Cush JJ. Early rheumatoid arthritis-Is there a window of opportunity? J Rheumatol 2007;34 (Suppl 80):1-7.
 
70) van der Helm-van Mil AHM, Delert J, Cessie SL, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis-moving toward individualized treatment decision-making. Arthritis Rheum 2008;58:2241-2347.
 
71) 武井修治, 今中宏之, 前野伸昭, ら:小児リウマチ性疾患における医療連携. 臨床リウマチ 2008:20:235-239.
 
P.46 掲載の参考文献
1) 七川歡次, 辻本正記, 大田 寛, ら. 慢性関節リウマチの死因調査. 昭和52年度骨・関節難病調査研究結果報告書. 大阪府衛生部, 大阪府特定疾患研究会, 大阪府骨・関節難病研究会. 昭和53年3月, 1978:5頁-29頁.
 
2) Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953;243:553-556.
 
3) 大田 寛. 慢性関節リウマチ患者の死因と寿命. リウマチ病セミナ III (七川歡次監修). 1992, p82-94, 大阪, 永井書店.
 
4) 大田 寛. RA患者の死因と薬剤治療. リウマチ病セミナーVIII (七川歡次監修). 1997, p240-246, 大阪, 永井書店.
 
5) 大田 寛. リウマトイド血管炎とRAの死因. リウマチ病セミナーXII (七川歡次監修). 2001, p30-39, 大阪, 永井書店.
 
6) Pinals RS. Survival in rheumatoid arthritis. Arthritis Rheum 1987;30:473-475.
PubMed
7) Cosh JA. Survival and death in rheumatoid arthritis. J Rheurnatol 1984;11:117-119.
PubMed
8) Allebeck P, Ahlhom A, Allander E Increased mortality among persons with rheumatoid arthritis, but where RA dose not appear on death certificate. Scand J Rheumatol 1981;10:301-306.
 
9) Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994:37:481-94.
PubMed
10) Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999;58:11-14.
PubMed
11) Kroot EJA, van Leeuwen MA, van Rijswijk MH, et al. No increased mortality in patients with rheumatoid arthritis:up to 10 years of follow up from disease onset. Ann Rheum Dis 2000;59:954-958.
 
12) Ward MM Recent Improvements in survival in patients with rheumatoid arthritis:better outcomes or different study designs? Arthritis Rheum 2001;44:1467-1469.
PubMed
13) Linos A, Worthington JW, O' Fallon WM, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota:A study of incidence, prevalence and mortality. Am J Epid 1980;111:87-98.
 
14) Jacobsson LT, Knowler WC, Pillemer S, et al. Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 1993;36:1045-1053.
PubMed
15) Kvalvik AG, Jones MA, Symmons DPM. Mortality in cohort of norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J rheumatol 2000;29:29-37.
 
16) Bjornadal L, Baecklund E, Yin L, et al. Decreasing mortality in patients with rheumatoid arthritis:Results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002;29:906-912.
PubMed
17) Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis. A population-based analysis of trends over 40 years. Arthritis Rheum 2003:48:54-58.
PubMed
18) Gonzalez A, Kremers HM, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-3587.
 
19) Wicks IP, Moore J, Fleming A. Australian mortality statistics for rheumatoid arthritis 1950-81:analysis of death certicifate data. Ann Rheum Dis 1988;47:563-569.
PubMed
20) Coste J, Jougla E. Mortality from rheumatoid arthritis in France, 1970-1990. Int J Epidemiol 1994; 23:545-552.
PubMed
21) Anderson ST. Mortality in rheumatoid arthritis:Do age and gender make a difference? Semin Arth Rheum 1996;25:291-296.
 
22) Reilly PA, Cosh JA, Maddison PJ, et al. Mortality and survival in rheumatoid arthritis:a 25 year prospective study of 100 patients. Ann Rheum Dis 1990;49:363-369.
PubMed
23) Goodson N. Coronary artery disease and rheumatoid arthritis. Current opinion in Rheumatology 2002;14:115-120.
PubMed
24) 澤井高志. 関節リウマチ (RA) における心病変. 第16回 (2005年) 近畿リウマチ病研究会記録集2006:47-55.
 
25) 川人 豊. 関節リウマチの心血管イベント. 臨床リウマチ2006;18:217-224.
 
26) 志水正敏RAと心血管イベント. リウマチ病セミナーXVIII (七川歡次監修). 2007, p 1-7, 大阪,永井書店.
 
27) 藤森一平. 慢性関節リウマチの死因. リウマチ外科1978;6:88-93.
 
28) 辻林啓幸, 膳 棟頭, 津山研一郎, ら. 在宅ねたきりRA患者の死亡調査-和歌山県南紀地区-. 臨床リウマチ1991;4:145-149
 
29) Hakoda M, Oiwa H, Kasagi F, et al. Mortality of rheumatoid arthritis in Japan:A longitudinal cohort study. Ann Rheum Dis 2005:64:1451-1455.
PubMed
30) Nakajima A, Inoue E, Singh G, et al. Mortality of rheumatoid arthritis in Japan based on a large observational cohort IORRA. ACR 抄録 2008:S514,
 
31) 吉澤久嘉, 工藤 洋, 岩野邦男, ら. 慢性関節リウマチの死因に関する研究-117RA死亡例の分析-リウマチ1990;30:255-263.
 
32) 鈴木 厚, 小井戸則彦, 大曽根康夫, ら. 慢性関節リウマチ140例の死因に関する検討. リウマチ1994; 34:601-607.
 
33) Shinomiya F, Mima N, Nanba K, et al. Life expectancies of japanese patients with rheumatoid arthritis:a review of death over a 20-year period. Mod Rheumatol 2008;165-169.
 
34) Prior P, Symmons DPM, Scott DL, et al. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-99.
 
35) Allebeck P:Increased mortality in rheumatoid arthritis. Scand J Rheumatol 1982:11:81-86.
PubMed
36) Duthie JJR, Brown PE, Truelove LH, et al. Course and prognosis in rheumatoid arthritis:a further report. Ann Rheum Dis 1964:23:193-204.
 
37) Monson RR, Hall AP. Mortality among arthritis. J Chronic Dis 1976;29:459-467.
PubMed
38) Mutru O, Laakso M, Isomaki HA, et al. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J 1985;290:1797-1799.
 
39) Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-714.
PubMed
40) Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years, Arthritis Rheuma 1984;27:864-872.
 
41) Uddin J, Kaus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheuma 1970;13:125-130.
 
42) Lewis P, Hazleman BL, Hanka R, et al. Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheuma Dis 1980;39:457-461.
 
43) Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis:have we made an impact in 4 decate? JRheumatol 1999;26:2529-2533.
 
44) Sakka T, Mottonen T, Hannonen P, et al. Mortality in early"sawtooth"treated rheumatoid arthritis patients during the first 8-14 years. Scand J Rheumatol 1999;28:282-287.
 
45) Symmons DPM, Jones MA, Scott DL, et al. Longterm mortality outcome in patients with rheumatoid arthritis. early presenters continue to do well. J Rheumatol 1998;25:1072-1077.
 
46) Wallberg-Jonsson S, Ohman M-L, Rantapaa-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 1997;24:445-451.
 
47) Callahan LF, Cordray DS, Wells G, et al. Formal education and five-year mortality in rheumatoid arthritis:mediation by helplessness scale scores. Arthritis Care Res 1996:9:463-472,
PubMed
48) Leigh JP, Fries JT. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991:18:1307-1312.
 
49) Pincus T, Callahan LF. The'side effects' of rheumatoid arthritis:Joint destruction, disability and early mortality. Br J Rheumatol 1993;32:28-37 (suppl1).
 
50) Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis:a 25 year prospective follow-up. J Rheumatol 1984;11:158-161.
 
51) Erhardt CC, Mumford PA, Vanables PJ. Factors predicting a poor life prognosis in rheumatoid arthritis:An eight year prospective study. Ann Rheum Dis 1989;48:7-13.
 
52) Scott DL, Symmons DPM, Coultor PL, et al. Long term outcome of treating rheumatoid arthritis:result after 20 years. Lancet 1987;1:1108-1111.
 
53) 山田昭夫. 慢性関節リウマチの生命予後-死因の分析からの予測-リウマチ科 1997;18:267-271.
 
54) 大田 寛, 七川歡次, 吉野良平, ら. 慢性関節リウマチの死因調査 (250症例). 臨床リウマチ1990;2:255-265.
 
55) Krause D, Schleusser B, Herborn G, et al. Response to Methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-20.
PubMed
56) Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis:a prospective study. Lancet 2002;359:1173-1177.
PubMed
57) Jacobsson LTH, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-675.
PubMed
58) Wasko MC, Hubert H, Lingala B, et al. All-cause mortality in RA. 第72回アメリカリウマチ学会抄録 2008:S276.
 
59) Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis:results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.
PubMed
60) van Halm VP, Nurmohamed MT, Twisk JWR, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis:a case control study. Arthritis Res Ther 2006;8:R151.
PubMed
61) Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006;55:531-536.
PubMed
62) Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-1218.
PubMed
63) Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumor necrosis factor antagonists. Ann Rheum Dis 2007;66:680-685.
PubMed
64) Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy:results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-2912
 
P.57 掲載の参考文献
1) Sweet RD. An acute febrile neutrophilic dermatosis. British J Dermatol 1964;76:349-56.
 
2) Crow KD, Kerdel-Vegas F. Rook AAcute febrile neutrophilic dermatosis Sweet's syndrome. Dermatologica 1969;139:123-34.
 
3) Uhara H, Saida T, Nakazawa H, Ito T. Neutrophilic dermatoses with acute myeloid leukemia associated with an increase of serum colony-stimulating factor. J Am Acad Dermatol 2008;59:S10-12.
PubMed
4) Govoni M, Colina M, Massara A, Trotta F. SAPHO syndrome and infection Autoimmun Rev 2009:8:256-259.
PubMed
5) Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases, Arch Dermatol 1991;127:1333-1338.
PubMed
6) Kanazawa N, Furukawa F. Autoinflammatory syndromes with a dermatological perspective. J Dermatol 2007;34:601-618.
PubMed
7) Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008;58:2432-2442.
 
8) 西山茂夫. 好中球性紅斑. 皮膚病アトラス (西山茂夫著). 1992, p71, 東京, 文光堂.
 
9) Itami S, Nishioka K. Sweet's syndrome in infancy. Br J Dermatol 1980:103:449-451.
PubMed
10) Cohen PR, Kurzrock R. Chronic myelogenous leukemia and Sweet syndrome. Am J Hematol 1989:32:134-137.
PubMed
11) Yamauchi PS, Turner L, Lowe NJ, et al. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006:54:S122-126.
PubMed
12) 澤井孝之, 西岡淳一. 慢性関節リウマチに合併したスウィート症候群. リウマチ病セミナーVI (七川歡次監修). 1995, p3-8, 大阪, 永井書店.
 
13) Harada Y, Egi Y, Honda Y, et al. [Multiple myeloma with Sweet disease developing from monoclonal gammopathy of undetermined significance and Sjogren syndrome]Rinsho Ketsueki 2001; 421:176-180.
 
14) Cohen PR, Kurzrock R. Sweet's syndrome:a review of current treatment options. Am J Clin Dermatol 2002;3:117-131.
PubMed
15) Matsunaga Y, Katayama I, Kadota J. Effect of clarithromycin on IL-8 formation by epidermal keratocytes Jpn J Antibiot 2000;53:68-69.
 
16) Matsunaga Y, Katayama I, Kadota J. Therapeutic effects of macrolides on patients with palmoplantar pustulosis, Jpn J Antibiot 2001;54:106-108.
 
17) Sayah A, English JC 3rd. Rheumatoid arthritis:a review of the cutaneous manifestations. J Am Acad Dermatol 2005:53:191-209.
PubMed
18) Smith ML, Jorizzo JL, Semble E, et al. Rheumatoid papules:lesions showing features of vasculitis and palisading granuloma. J Am Acad Dermatol 1989;20:348-52.
PubMed
19) Ackerman AB. Rheumatoid neutrophilic dermatitis Histologic diagnosis of inflammatory skin diseases, A method by pattern analysis. Philadelphia, Lea-Febiger, 1978;437.
 

骨関節, 脊椎, 神経

P.68 掲載の参考文献
1) Sidney AS, Wolfgang L. How irritating:the role of TRPA1 in sensing cigarette smoke and aerogenic oxidants in the airways. J Clin Invest 2008:118:2383-2386.
 
2) Hirsch C. Studies on the mechanism of low back pain. Acta Orthop Scand 1953;22:184-231.
 
3) Nade S, Bell S, Wyke BD. The innervation of the lumbar spine joints and its significance. J Bone Joint Surg 1980:62B:225-261.
 
4) Bogduk N, Tynan W, Wilson AS. The nerve supply to the human lumbar intervertebral disc. J Anat 1981;132:2-8.
 
5) Humzah MD, Soames RW. Human intervetebral disc:structure and function. Ant Rec 1988;220:103-113.
 
6) Groen GJ, Baljet B, Drukker J. The nerves and nerve plexuses of human vertebral column. Am J Anat 1990;188:282-296.
PubMed
7) Kojima Y, Maeda T, Arai R, et al. Nerve supply to the posterior longitudinal ligament and the intervertebral disc of the rat vertebral column as studied by acetylcholinesterase histochemistry. I. Distribution in the lumbar region. J Anat 1990;169:237-246.
 
8) Kojima Y, Maeda T, Arai R, et al. Nerve supply to the posterior longitudinal ligament and the intervertebral disc of the rat vertebral column as studied by acetylcholinesterase histochemistry. II. Regional differences in the distribution of the nerve fibers and their origins. J Anat 1990;169:247-256.
 
9) Imai S, Hukuda S, Maeda T. Dually innervating nociceptive networks in the rat posterior longitudinal ligaments. Spine 1995:20:2135-2140.
 
10) Imai S, Konttinen YT, Tokunaga Y, et al. An ultrastructural study of CGRP-immunoreactive nerve fibres innervating rat posterior longitudinal ligament. A morphological basis for their possible efferent actions. Spine 1997;22:1941-1947.
 
11) Imai S, Konttinen YT, Tokunaga Y, et al. Tyrosine hydroxylase immunoreactive nerve fibres in rat posterior longitudinal ligament. J Auton Nerv Syst 1997:63:51-60.
PubMed
12) Imai S, Tokunaga Y, Maeda T, et al. CGRP-, SP-and TH-immunoreactive innervation of rat bone marrows. An immunohistochemical and ultrastructural investigation on possible efferent and afferent mechanisms. J Orthop Res 1997:15:133-140.
 
13) Yirmiya R, Goshen I, Bajayo A, et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A 2006;103:16876-16881.
PubMed
14) Dina OA, McCarter GC, de Coupade C, et al. Role of the sensory neuron cytoskeleton in second messenger signaling for inflammatory Pain. Neuron 2003:39:613-624.
PubMed
P.75 掲載の参考文献
1) Rothschild BM, Tanke D, Carpenter K. Tyrannosaurs suffered from gout Nature 1997;387:357.
PubMed
2) McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961;54:452-460.
PubMed
3) Daniel J McCarty. Urate Crystals, Inflammation, and Colchicine. ARTHRITIS & RHEUMATISM 2008;58:S20-S24.
PubMed
4) Kohn NN, Hughes RE, McCarty DJ. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients:"thepseudogout syndrome". II. Identification of crystals. Ann Intern Med 1962:56:738-745.
PubMed
5) Siegel SA, Hummel CF, Carty RP. The role of nucleoside triphosphate pyrophosphohydrolase in in vitro nucleoside triphosphate-dependent matrix vesicle calcification. J Biol Chem 1983;25:258 (14):
 
6) Pendleton A, Johnson MD, Hughes A, et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002;71:933-940.
PubMed
7) Andrew LJ, Brancolini V, de la Pena LS, et al. Refinement of the chromosome 5p locus for familial calcium pyrophosphate dihydrate deposition disease. Am J Hum Genet 1999;64:136-134.
PubMed
8) Martinon F, P_trilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-241.
 
9) 奥 和美. 軟骨石灰化症と脊椎. リウマチ病セミナーII (七川歡次監修). 1991, p155-164, 大阪, 永井書店.
 
P.81 掲載の参考文献
1) 石澤命仁. histiocytosis. リウマチ病セミナーXI (七川歡次監修). 2000, p86-94, 大阪, 永井書店.
 
2) Favara BE, Feller AC, Paul M, et al. Contemporary classification of histiocytic disorders. The WHO committee on histiocytic/reticulum cell proliferations. Reclassification Work Group of the Hstiocyte Society. Med Pediatr Oncol 1997;29:157.
 
3) De Young, Unni KK. Langerhans cell histiocytosis. Fletcher CDM, Unni KK, Mertens F ed. WHO classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon, IARCPress, 2002:345-346.
 
4) Tazi A. Adult pulmonary Langerhans cell histiocytosis. Eur Respir J 2006;27:1272-1285.
PubMed
5) Braier J, Latella A, Balancini B, et al. Outcome in children with pulmonary Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:765-769.
PubMed
6) Bernstrand C, Cederlund K, Sandstedt B, et al. Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol 2001:36:459-468.
PubMed
7) Chikwava K, Jaffe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatric and Developmental Pathology 2004;7:607-614.
PubMed
8) Bahtia S, Nesbit ME, Egeler RM, et al. Epidemiological study of Langerhans cell histiocytosis in children. J Pediatr 1997:130:774-784.
 
9) Willman CL, Busque L, Griffith B, et al. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med 1994;331:154-160.
PubMed
10) Fadeel B, Henter J-I. Langerhans-cell histiocytosis:neoplasia or unbridled inflammation? Trends Immunol 2003:24:409-411.
 
11) Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans cell histiocytosis. Molecular analysisof clonality. Am J Surg Pathol 2001;25:630-636.
 
12) Da Costa CET, Egeler RM, Hoogeboom M, et al. Differences in telomerase expression by the CD1 a+ cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease. J Pathol 2007;212:188-197.
 
13) Bechan GI, Meeker AM, De Marzo AM, et al. Telomere length shortening in Langerans cell histiocytosis. British Jounal of Haematlogy 2007;140:420-428.
 
14) da Costa CET, Annels NE, Faaij CMEM, et al. Presence of osteoclst-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 2005;201:687-693.
 
15) Goo HW. Whole-body MRI of Langerhans cell histiocytosis:comparison with radiography and bone scintigraphy. Pediatr Radiol 2006:36:1019-1031.
PubMed
16) Ribeiro M-J, Idbaih A, Thomas C, et al. 18F-FDG PET in neurodegenerative Langerhans cell histiocytosis. Results and potential interest for an early diagnosis of the disease. J Neurol 2008;255:575-580.
 
17) Papagelopoulos PJ, Currier BL, Galans E, et al. Vertebra plana caused by primary Ewing sarcoma:case report and review of the literature. J Spinal Disord & Techniques 2002;15:252-257.
 
18) Allen CE, McClain KL. Langerhans cell histiocytosis:areview of past, current and future therapies. Drugs of Today 2007;43:627-643.
 
19) Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis. Results from the Japan Langerhas Cell Histiocytosis Study Group-96 Protocol Study. Cancer 206:107:613-619.
 
20) Henter JI, Tondini C, Pritcchard J. Histiccyte disorders. Critical Reviews in oncology/hematology 2004;50:157-174.
 
21) Bernstrand C, Sandstedt B, Ahstrom L, et al. Long-term follow-up of Langerhans cell histiocytosis:39 years' experience at a single centre. Acta Pediatr 2005:94:1073-1084.
 
22) Weitzman S, Egeler RM. Langerhans cell histiocytosis:update for the pediatrician. Current Opinion in Pediatrics 2008:20:23-29.
PubMed
23) Olschewsky T, Seegenschmiedt MH. Radiotherapy for bony manifestations of Langerhans cell histocytosis. Review and proposal for an international registry. Strahlenther Oncol 2006:182:72-79.
 
24) Ghanem I, Tolo VT, D'Ambra P, et al. Langerhans cell histiocytosis of bone in chidren and adolescents. J Pediatr Orthop 2003;23:124-130.
 
25) Lau LMS, Stuurman K, Weitzman S. Skeletal Langerhans cell histiocytosis in children:permanent consequences and health-related quality of life in long-term survivors. Pediatr Blood Cancer 2008:50:607-612.
PubMed
26) Raab P, Hohmann F, Kuhl J, et al. Vertebral remodeling in eosinophilic granuloma of the spine. A long-term follow-up. Spine 1998;12:1351-1354.
PubMed
27) Garg S, Mehta S, Dormans JP. Langerhans cell histiocytosis of the spine in children. Long-term follow-up. J Bone Joint Surg Am 2004;86:1740-1750.
PubMed
28) Tanaka N, Fujimoto Y, Okuda T, et al. Langerhans cell histiocytosis of the altas. A report of three cases. J Bone Joint Surg Am 2005;87:2313-2317.
 
29) Puigdevall M, Bosio S, Hokama J, et al. Langerhans cell histiccytosis of the atlas in the pediatric spine:total reconstruction of the bone lesion after nonoperative treatment. A report of two cases. J Bone Joint Surg Am 2008;90:1994-1997.
 
30) Zelger BWH, Sidoroff A, Orchard G, et al. Non-Langerhans cell histiocytoses:A new unifying concept. Am J Dermatpathol 1996:18:490-504.
 
31) Trotta F, Castellino G, Lo Monaco A. Multicentric reticulohisticcytsis. Best Practice & Research Clinical Rheumatology 2004;18:759-772.
PubMed
32) Sakamoto A, Nagamine R, Maeda T, et al. Multicentric rticulohistiocosis with hydroarhrosis in both knee joints:disase stabilization with synovectomy, and medication with a steroid and low-dose methotrexate. Mod Rheumatol 2002:12:155-159.
 
33) Sellam J, Deslandre CJ, Dubreuil F, et al. Refractory multicentric reticulohstiocytosis treated by infliximab:two cases. Clin Exp Rheumatol 2005;23:97-99.
PubMed
34) Mavragani CP, Batziou K, Aroni K, et al. Alleviation of polyarticular syndrome in multicentric reticulohistiocytosis with intravenous zoledronate. Ann Rheum Dis 2005;64:1521-1522.
PubMed
35) Goto H, Inaba M, Kobayashi K, et al. Successful treatment of multicentric reticulohistiocytosis with alendronate. Evidence for a direct ffect of bisphosphonate on histiocytes. Arthritis Rheum 2003;48:3538-3541.
 
36) Kenn W, Eck M, Allolio B, et al. Erdheim-Cester disease:evidence for a disease entity different from Langerhans cell histiocytosis? Three cases with detaild radiological and immunhistochemical analysis. Human Pathol 2000:31:734-739.
 
37) Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease. Arthritis Rheum 2006;54:4018-4022.
PubMed
P.90 掲載の参考文献
1) Dotter WE. Little league shoulder. Gutrie Clin Bulletin 1953;23:68-72.
 
2) Adams JE. Little league s houlder-osteochondros is of the proximal humeral epiphysis in boy baseball pitchers. Calif Med 1966;105:22-25,
 
3) Cahill BR. Little league shoulder-lesion of the proximal humeral epiphyseal plate. J Sport Med 1974; 2:150-152.
 
4) Weseley MS, Barenfeld PA. Ball thrower:s fracture of the humerus. Clin Orthop 1969:64:153-156.
 
5) 信原克哉. 肩-その機能と臨床. 第3版. 2001, p229-242, 東京, 医学書院.
 
6) Atwater AE. Biomechanics of overarm throwing injuries. Exere Sport Sci Rev 1979;7:43-85.
 
7) 信原克哉.投球による肩の障害. 整形外科1979;30:605-610.
 
8) McLeod WD. The pitching mechanism. In:Zarins B, Andrews JR, Carson WG (eds). Injuries to the Throwing Arm. Philadelphia, WB Saunders, 1985.
 
9) Malone TR (ed). Throwing Injuries. Baltimore, William&Wilkins, 1989.
 
10) Fleisig GS, Andrews JR, Dillman CJ, et al. Kinetics of baseball pitching with implications about in-jury mechanisms. Am J Sports Med 1995;23:233-239,
 
11) Snyder SJ, Karzel RP, Del Pizzo W, et al. SLAP lesions of the shoulder. Arthroscopy 1990:6:274-279.
PubMed
12) Nobuhara K. The Shoulder-lts Function and Clinical Aspect. New Jersey, World Scientific, 2004.
 
13) Papas AM, Zawacki RM, Sullivan TJ. Biomechanics of baseball pitching. Am J Sports Med 1985; 13:216-222.
 
14) Tullos HS, King JW. Throwing mechanism in sports. Orthop Clin North Am 1973:4:709-720.
PubMed
15) Wilk KE, Andrews JR, Arrigo CA, et al. The strength characteristics of internal and external rotator muscles in professional baseball pitchers. Am J Sports Med 1993;21:61-66.
PubMed
16) Older MWJ. Distension arthrography of the shoulder joint shoulder surgery. Heidelberg, Springer Verlag, 1982.
 
17) Resnik CS, Fronek J, Frey C, et al. Intra-articular pressure determination during glenohumeral joint arthrography. Preliminary investigation. Invest Radiol 1984;19:45-50.
 
18) 橋本 卓, 池田 均, 信原克哉, ら. 肩関節内圧について. 肩関節1990;14:245-248.
 
19) Nobuhara K, Ikeda H. Rotator Interval Lesion. Clin Orthop 1990;223:44-50.
 
20) Harryman DT II, Sidles JA, Matsen FAM. The role of the rotator interval capsule in passive motion and stability of the shoulder. J Bone Joint Surg 1992:74-A;53-66.
 
21) Glousman RE. Instability versus impingement syndrome in throwing athlete. Orthop Clin North Am 1993;24:89-99.
PubMed
22) 立花 孝, 西川仁史, 松岡俊哉, ら. 投球動作の分析-体幹の捻れと投球腕の鞭打ち様運動. 臨床スポーツ医学1992;9:219-224.
 
23) 中村康雄, 中村真里, 中溝寛之, ら. ボールリリース時の肩関節の投球姿勢と肩関節負荷との関係. 肩関節2004;28:329-332.
 
24) 中溝寛之, 中村真里, 信原克哉, ら. 子供の投球動作の特徴. 肩関節2004;28:355-358.
 
25) Sabick MB, Kim YK, Torry MR, et al. Biomechanics of the shoulder in youth baseball pitchers:Im-plications for the development of proximal humeral epiphysiolisis and humeral retrotorsion. Am J Sports Med 2005;33:1716-1722.
 
P.97 掲載の参考文献
1) McCrory P (editorial). The 209-210. "piriformis syndrome"-myth or reality? Br J Sports Med 2001 35
PubMed
2) Stewart JD. The piriformis syndrome is overdiagnosed. Muscle Nerve 2003;28:644-646.
PubMed
3) Durrani Z, Winnie AP. Piriformis muscle syndrome:an underdiagnosed cause of sciatica. J Pain Symptom Manag 1991:6:374-379.
 
4) Fishman LM, Schaefer MP. The piriformis syndrome is underdiagnosed. Muscle Nerve 2003;28:646-649.
PubMed
5) Buttaravoli P.115筋筋膜痛症候群-線維筋痛症. マイナーエマージェンシー (大滝純司訳). 2009, p482-491, 東京, 医歯薬出版.
 
6) 西林保朗. Piriformis syndrome. リウマチ病セミナーII (七川歡次監修). 1991, p117-136, 大阪永井書店.
 
7) Pecina HI, Boric I, Smoljanovic Y, et al. Surgical evaluation of magnetic resonance imaging findings in piriformis muscle syndrome. Skeletal Radiol 2008:37:1019-1023.
 
8) 西林保朗. 股関節周囲炎. リウマチ病セミナーXVI (七川歡次監修). 2005, p84-97, 大阪, 永井書店.
 
9) Rodrigue T, Hardy RW. Diagnosis and treatment of piriformis syndrome. Neurosurg Clin N Am 2001;12:311-319.
PubMed
10) Silver JK, Leadbetter WB. Plriformis syndrome:assessment of current practice and literature review. Orthopedics 1998;21:1133-1135.
PubMed
11) Papadpopoulos EC, Khan SN. Piriformis syndrome and low back pain:anew classification and re-view of the literature. Orthop Clin North Am 2004;35:65-71.
 
12) Read MTF (letters). The"piriformis syndrome"-myth or reality? Br J Sports Med 2002;36:76.
PubMed
13) 西林保朗, 小形晶子. 筋筋膜痛症候群. リウマチ病セミナーXVII (七川歡次監修). 2006, p101-113, 大阪, 永井書店.
 
14) Steiner C, Staubs C, Ganon M, et al. Piriformis syndrome:Pathogenesis, diagnosis, and treatment. JAm Osteipath Assoc 1987;87:318-323.
 
15) Giesecke T, Geisser ME. Chronic low back pain. Wallace DJ, Clauw DJ, ed. Fibromyalgia and other central pain syndromes. Philadelphia;Lippincott Williams Wilkins;2005:241-257.
 
16) 西林保朗. 線維筋痛症のレゾンデートル-運動器疾患患者の全人的ケアへのいざない-. リウマチ病セミナーXIX (七川歡次監修). 2008, p58-67, 大阪, 永井書店.
 
17) Yunus MB. The concept of central sensitivity syndromes. Wallace DJ, Clauw DJ ed. Fibromyalgia and other central pain syndromes. Philadelphia:Lippincott Williams Wilkins;2005:29-44.
 
18) Wong DA, ed. Fibrositis (fibromyalgia) and myofascial pain syndrome. 68-69, Macnab:s backache. 4th ed. Philadelphia:Lippincott Williams Wilkins;2007.
 
19) AkCali D, Ta§A, Cizmeci P, et al. Reflex sympathetic dystrophy secondary to piriformis syndrome:acase report (inTurkish). Agri 2009;21:75-79.
 
20) Cayea D, Perera S, Weiner DK. Chronic low back pain in older adults:What physicians know, what they think they know, and what they shuld be taught. J Am Geriatr Soc 2006:54:1772-1777.
 
21) 大谷晃司, 菊地臣一. 梨状筋症候群. 整・災害2008;51:569-574.
 
22) Boyajian-O'Neil LA, McClain RL, Coleman MK, et al. Diagnosis and management of piriformis syndrome:an osteopathic approach. J Am Osteopath Assoc 2008;108:657-664.
 
23) Kulcu DG, Naderi S. Differential diagnosis of intraspinal and extraspinal non-discogenic sciatica. J Clin Neurosci 2008;15:1246-1252.
PubMed
24) Nui CC, Lai PL, Fu TS, et al. Ruling out piriformis syndrome before diagnosing lumbar radiculopathy. Chang Gung Med J 2009:32:182-187.
 
25) Bustamante S, Houlton PG. Swelling of the leg, deep venous thrombosis and the piriformis syndrome. Pain Res Manag 2001;6:200-203.
PubMed
26) Campbell WW, Landau ME. Controversial entrapment neuropathies. Neurosurg Clin N Am 2008; 19:597-608.
 
27) Teil RL. Piriformis and related entrapment syndromes:myth&fallacy. Neurosurg Clin N Am 2008; 19:623-627.
 

燐・カルシウム代謝

P.106 掲載の参考文献
1) Imura H, Seino Y, Nakagawa S, et al. Diabetic osteopenia in Japanese-a geographic study-. J Japan Diabet Soc 1987;30:9924-9929.
 
2) Levin ME, Boisseau VC, Avioli LV. Effect of diabetes mellitus on bone mass in juvenile and adult on-set diabetes. N Engl J Med 1976;294:241-244.
 
3) Inaba M, Okuno S, Kumeda Y, et al. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005;76:256-260.
PubMed
4) Yamamoto M, Yamaguchi T, Yamauchi M, et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab (ln press)
 
5) Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type l and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505.
 
6) Heath H, Melton LJ, Chu CP. Diabetes mellitus and risk of skeletal fracture. N Engl J Med 1980; 303:567-570.
PubMed
7) Melton III LJ, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes:update of a population-based study. J Bone Miner Res 2008;23:1334-1342.
 
8) Horcajada-Molteni MN, Chanteranne B, Lebecque P, et al. Amylin and bone metabolism in streptozo-tocin-induced diabetic rats. J Bone Miner Res 2001;16:958-965.
 
9) Lenchik L, Register TC, Hsu FC, et al:Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003;33:646-651.
PubMed
10) Saito M, Fujii K, Mori Y, et al:Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006:17:1514-1523.
PubMed
11) Kraukauer JC, Mckenna MJ, Buderer NF, et al. Bone loss and bone turnover in diabetes. Diabetes 1995;44:775-782.
 
12) Inaba M, Terada M, Koyama H, et al. Influence of high glucose on 1, 25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 1995:10:1050-1056.
 
13) Yoshida O, Inaba M, Terada M, et al. Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 1995;21:201-204.
PubMed
14) Inaba M, Terada M, Nishizawa Y, et al. Protective effect of aldose reductase inhibitor against bone loss in galactose-fed rats:Possible involvement of polyol pathway in bone metabolsim. Metabolism 1999;48:904-909.
 
15) Inaba M, Nagasue K, Okuno S, et al. Impaired secretion of parathyroid hormone, but not refractoriess of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 2002;39:1261-1269.
 
16) Yamada S, Inaba M, Goto H, et al. Associations between physical activity, peripheral atherosclerosis and bone status in healthy Japanese women. Atherosclerosis 2006;188:196-202.
PubMed
17) Ishida H, Cunninghum NS:The number of 1, 25-dihydroxyvitamin D3 receptor is decreased in both intestine and kidney of genetically diabetic db/db mice. Endocrinology 1988;122:2436.
 

検査法

P.113 掲載の参考文献
1) Shapiro JS. The wrist in rheumatoid arthritis. Hand Clin 1996;12:477-498.
PubMed
2) Kushner DM, Braunstein EM, Buckwalter KA, et al. Carpal instability in rheumatoid arthritis. Can Assoc Radiol J 1993:44:291-295.
PubMed
3) Muramatsu K, Ihara K, Tanaka H, et al. Carpal instability in rheumatoid wrists. Rheumatol Int 2004;24:34-36.
PubMed
4) Shapiro JS. A new factor in the etiology of the ulnar drift. Clin Orthop 1970:68:32-43.
PubMed
5) Taleisnik J. Rheumatoid synovitis of the volar compartment of wrist joint:its radiological signs and its contribution to wrist and hand deformity. J Hand Surg[Am] 1979:4:526-535.
PubMed
6) Flury MP, Herren DB, Simmen BR. Rheumatoid arthritis of the wrist. Classification related to the natural course. Clin Orthop Relat Res 1999;366:72-77.
 
7) Van Vugt RM, van Jaarsveld CH, Hofman DM, et al. Patterns of disease progression in the rheumatoid wrist:along-term follow-up. J Rheumatol 1999;26:1467-1473.
 
8) Shapiro JS. Wrist involvement in rheumatoid arthritis swanneck deformity. J Hand Surg[Am] 1982;7:484-491.
PubMed
9) Youm Y, McMurtry RY, Platt AE. Kinematics of the wrist. An experimental study of radial-ulnar deviation and flexion-extension. J Bone Joint Surg Am 1978;60-A:423-431.
 
10) Ochi T, Iwase R, Kimura T, et al. Effect of early synovectomy on the course of rheumatoid arthritis. JRheumatol 1991;18:1794-1798.
PubMed
11) Lorensen WE, Cline HE. Marching cubes:ahigh resolution 3D surface construction algorithm. Computer Graphics 1987:21:163-169.
 
12) Goto A, Moritomo H, Murase T, et al. In vivo three-dimensional wrist motion analysis using magnetic resonance imaging and volume-based registration. J Orthop Res 2005;23:750-756.
PubMed
13) Oka K, Moritomo H, Murase T, et al. Patterns of carpal deformity in scaphoid nonunion:a3-dimensional and quantitative analysis. J Hand Surg[Am] 2005;30:1136-1144.
 
14) Belsole RJ, Hilbelink DR, Llewellyn JA, et al. Mathematical analysis of computed carpal models. J Orthop Res 1988;6:116-122.
PubMed
15) Belsole RJ, Hilbelink DR, Llewellyn JA, et al. Carpal orientation from computed reference axes. J Hand Surg[Am] 1991;16:82-90.
PubMed
16) Schuind FA, Linscheid RL, An KN, et al. A normal data base of posteroanterior roentgenographic measurements of the wrist. J Bone Joint Surg Am 1992;74A:1418-1429.
 
17) Palmer AK. Fractures of the distal radius. In Green DP (ed):Operative Hand Surgery, ed 3.:New York:Churchill Livingstone:1993:929-971.
 
18) Cooney WP, Garcia-Elias M, Dobyns JH. Anatomy and mechanics of carpal instability. Surgical Rounds for Orthopedics 1989;3:15-25.
 
19) Mizuseki T, Ikuta Y. The dorsal carpal ligaments:their anatomy and function. J Hand Surg[Br] 1989;14-B:91-98.
 
20) Moritomo H, Murase T, Goto A, et al. In vivo three-dimensional kinematics of the midcarpal joint of the wrist. J Bone Joint Surg Am 2006:88-A:611-621.
PubMed
21) Arimitsu S, Murase T, Hashimoto J, et al. A three-dimensional quantitative analysis of carpal deformity in rheumatoid wrists. J Bone Joint Surg 2007;89B:490-494.
 
22) 有光小百合, 菅本一臣. リウマチ手関節の手根配列異常に対する3次元的定量評価. リウマチ科2007;38:1-6.
 
23) Arimitsu S, Sugamoto K, Hashimoto J, et al. Analysis of radiocarpal and midcarpal motion in stable and unstable rheumatoid wrists using 3-dimensional computed tomography. J Hand Surg[Am] 2008;33:189-197.
PubMed

生物学的反応

P.122 掲載の参考文献
1) 井田弘明, 江口勝美. 新しい疾患概念'自己炎症症候群'. 日本臨床2009;67:626-636.
 
2) Gershoni-Baruch R, Shinawi M, Leah K, et al. Familial Mediterranean fever:prevalence, penetrance and genetic drift. Eur J Hum Genet 2001;9:634-637.
PubMed
3) Simon A, Mariman EC, van der Meer JW, et al. A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. Am J Med 2003;114:148-152.
PubMed
4) Drenth JP, van der Meer JW. The inflammasome-a linebacker of innate defense. N Engl J Med 2006;355:730-732.
PubMed
5) Hoffman HM, Simon A. Recurrent febrile syndromes:what a rheumatologist needs to know. Nat Rev Rheumatol 2009:5:249-256.
PubMed
6) Meng G, Zhang F, Fuss I, et al. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th 17cell-dominant immune responses. Immunity 2009;30:860-874.
 
7) Fritz JH, Ferrero RL, Philpott DJ, et al. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006;7:1250-1257.
 
8) Brydges S, Kastner DL. The systemic autoinflammatory diseases:inborn errors of the innate immune system. Curr Top Microbiol Immunol 2006;305:127-160.
PubMed
9) Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 2006;6:183-195.
PubMed
10) Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-241.
PubMed
11) Bernot A, Clepet C, Dasilva C, et al. Nat Genet. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31,
PubMed
12) Sugiura T, Kawaguchi Y, Fujikawa S, et al. Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. Mod Rheumatol 2008;18:57-59.
 
13) Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-1712.
PubMed
14) Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998;351:659-664.
PubMed
15) Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001;345:1748-1757.
PubMed
16) Miyagawa S, Kitamura W, Morita K, et al. Association of hyperimmunoglobulinaemia D syndrome with erythema elevatum diutinum. Br J Dermatol l 993;128:572-574.
 
17) Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999;22:178-181.
 
18) Drenth JP, Prieur AM. Occurrence of arthritis in hyperimmunoglobulinaemia D. Ann Rheum Dis 1993:52:765-766.
PubMed
19) Drenth JP, Powell RJ. Hyper-IgD syndrome and familial Hibernian fever are true periodic fever syndromes. J Pediatr 2000;137:438-439.
PubMed
20) McDermott MF, Frenkel J. Hereditary periodic fever syndromes. Neth J Med 2001;59:118-125.
PubMed
21) Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS):emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002;81:349-368.
PubMed
22) Drewe E, Huggins ML, Morgan AG, et al. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004;43:1405-1408.
PubMed
23) 井田弘明, 宮下賜一郎, 和泉泰衛ら. 本邦初のTNF receptor-associated periodic syndrome (TRAPS) の一家系. リウマチ2003;43:414.
 
24) Kusuhara K Nomura A Nakao F, et al Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr 2004;163:30-32.
 
25) Ida H, Kawasaki E, Miyashita T, et al. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily I A (TNFRSF l A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology (Oxford) 2004;43:1292-1299.
 
26) Horiuchi T, Tsukamoto H, Mitoma H, et al. Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese. Int J Mol Med 2004;14:813-818.
PubMed
27) Stojanov S, Kastner DL. Familial autoinflammatory diseases:genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005;17:586-599.
PubMed
28) Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr. 1985:107:689-93.
 
29) Rotenstein D, Gibbas DL, Majmudar B, et al. Familial granulomatous arteritis with polyarthritis of juvenile onset. N Engl J Med 1982;306:86-90,
PubMed
30) Pastores GM, Michels VV, Stickler GB, et al. Autosomal dominant granulomatous arthritis, uveitis, skin rash, and synovial cysts. J Pediatr 1990;117:403-408.
PubMed
31) Gattorno M, Federici S, Pelagatti MA, et al. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 2008;28:S73-83.
PubMed
P.131 掲載の参考文献
1) Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998:14:59-88.
PubMed
2) Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000;407:530-535.
PubMed
3) Hey PJ, Twells RC, Phillips MS, et al. Cloning of a novel member of the low-density lipoprotein receptor family. Gene 1998;216:103-111.
PubMed
4) He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling:arrows point the way. Development 2004;131:1663-1677.
PubMed
5) Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
PubMed
6) Ikeda S, Kishida S, Yamamoto H, Murai H, et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998:17:1371-1384.
PubMed
7) Kikuchi A. Roles of Axin in the Wnt signalling pathway. Cell Signal 1999;11:777-788.
PubMed
8) Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism, Cell 2002;108:837-847.
 
9) Kitagawa M, Hatakeyama S, Shirane M, et al. An F-box protein, FWD l, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 1999;18:2401-2410.
 
10) Hurlstone A, Clevers H. T-cell factors:turn-ons and turn-offs. EMBO J 2002:21:2303-2311.
PubMed
11) Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signalling:diseases and therapies. Nat Rev Genet 2004;5:691-701.
PubMed
12) Miller JR, Hocking AM, Brown JD, et al. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+pathways. Oncogene 1999;18:7860-7872.
PubMed
13) Ishitani T, Kishida S, Hyodo-Miura J, et al. The TAK 1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca (2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 2003;23:131-139.
 
14) Kishida S, Yamamoto H, Kikuchi A. Wnt-3a and Dvl induce neurite retraction by activating Rho-associated kinase. Mol Cell Biol 2004;24:4487-4501.
PubMed
15) Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-1521.
PubMed
16) Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-523.
PubMed
17) Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-19.
PubMed
18) Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003;72:763-771.
PubMed
19) Babij P, Zhao W, Small C, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003:18:960-974.
 
20) Koay MA, Brown MA. Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton. Trends Mol Med 2005;11:129-137.
PubMed
21) Hartikka H, Makitie O, Mannikko M, et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 2005;20:783-789.
 
22) Mizuguchi T, Furuta I, Watanabe Y, et al. LRP5, low-density-1ipoprotein-receptor-related protein 5, is a determinant for bone mineral density. J Hum Genet 2004:49:80-86.
 
23) Urano T, Shiraki M, Ezura Y, et al. Association of a single-nucleotide polymorphism in low-density lipoprotein receptor-related protein 5 gene with bone mineral density. J Bone Miner Metab 2004;22:341-345.
PubMed
24) Koay MA, Woon PY, Zhang Y, et al. Influence of LRP5 polymorphisms on normal variation in BMD. JBone Miner Res 2004;19:1619-1627.
 
25) Kato M, Patel MS, Levasseur R, et al. Cbfa 1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lm5, a Wnt coreceptor. JCell Biol 2002:157:303-314.
 
26) van Meurs JB, Rivadeneira F, Jhamai M, et al. Common genetic variation of the low-density lipopro-tein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J Bone Miner Res 2006;21:141-150.
 
27) Sapkota G, Alarcon C, Spagnoli FM, et al. Balancing BMP signaling through integrated inputs into the Smad l linker. Mol Cell 2007;25:441-454.
 
28) Fuentealba LC, Eivers E, Ikeda A, et al. Integrating patterning signals:Wnt/GSK3 regulates the duration of the BMP/Smad l signal. Cell 2007;131:980-993.
 
29) Akiyama H, Lyons JP, Mori-Akiyama Y, et al. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev 2004:18:1072-1087.
PubMed
30) Corr M. Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 2008;4:550-556.
PubMed
31) Walsh NC, Crotti TN, Goldring SR, et al. Rheumatic diseases:the effects of inflammation on bone. Immunol Rev 2005;208:228-251.
 
32) Sen M, Lauterbach K, El-Gabalawy H, et al. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci 2000;97:2791-2796.
PubMed
33) Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163.
PubMed
34) 森 幹士. 抗TNF-αによる滑膜炎症と骨・軟骨破壊との乖離.リウマチ病セミナーXIX (七川歡次監修). 2008, p136-142, 大阪, 永井書店.
 
35) Sen M, Reifert J, Lauterbach K, et al. Regulation of fibronectin and metalloproteinase expression by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum 2002;46:2867-2877.
PubMed
36) Schett G, Zwerina J, David JP. The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 2008:4:473-480.
PubMed
37) Polzer K, Diarra D, Zwerina J, Schett G. Inflammation and destruction of the joints-the Wnt pathway. Joint Bone Spine 2008;75:105-107.
PubMed
P.140 掲載の参考文献
1) 和田正信, 松永 智. 筋収縮とエネルギー供給系. 入門運動生理学 (勝田 茂編). 2008, p1-11, 東京, 杏林書院.
 
2) 八田秀雄. 1章血中乳酸濃度はどんな意味があるのか. 乳酸をどう活かすか. 2008, pl-12, 東京, 杏林書院.
 
3) 征矢英昭. 運動ストレスとACTH分泌. 運動とホルモン (井澤鉄也編). 2001, p35-66, 東京, ナップ.
 
4) Tsukahara A, Toda T, Suzuki S, et al. Adrenergic stimulation simultaneously induces the expansion of granulocytes and extrathymic T cells in mice. Biomed Res 1997;18:237-246.
 
5) Bruunsgaard H, Galbo H, Ha (kjaer KJ, et al. Exercise-induced in serum interleukin-6 in humans is related to muscle damage. Journal of Physiology 1997:499. 3. 833-841.
 
6) 足立 稔, 熊谷秋次. 免疫機能と運動・スポーツ. 健康スポーツ科学 (浅野勝己, ら編). 2007, p84-91, 東京, 文光堂.
 
7) Thune I, Furberg A. Physical activity and cancer risk:dose-response and cancer, all site and site spe-cific. Med Sci Spoerts Exerc 2001;33:530-550.
 
8) Martinsen EW, Morgan WP. 運動の抗うつ効果. 身体活動とメンタルヘルス (竹中晃二, ら監訳). 1999, p127-142, 東京, 大修館書店.
 
9) Blumenthal JA, Babyak MA, Moore KA, et al. Effects of Exercise Training on Older Patients With Major Depression. ARCH INTERN MED 1999:159:2379-2356.
 
10) Babyak M, Blumenthal J, Herman S, et al. Exercise Treatment for Depression:Maintenance of Therapeutic Benefit at 10 Months. Psychosomatic Medicine 2000;62:633-638.
PubMed
11) Taylor LA, Fishman ML. Corticotropin-releasing hormone. The new England journal of medicine 1988;319:213-222.
 
12) Nemeroff CB, Widerloev E, Bissette G, et al:Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342.
 
13) Alexander SL, Irvine CH, Ellis MJ, et al:The effect of acute exercise on the secretion of corticotrophin-releasing factor, arginine vasopressin, and adrenocorticotropin as measured in pituitaryvenous blood from the house. Endocrinology 1991;128, 65-72.
 
14) Smoak B, Deuster P, Rabin D:Corticotropinreleasing hormone is not the sole factor mediating exercise-induced adrenocorticotropin release in humans. J Clin Endocrinol Metab 1991;73, 302-306.
 
15) 征矢英昭, 川島 均, 斉藤 剛, ら. 運動時のストレス反応とACTH分泌:視床下部による分子調節. ホルモンと臨床 2006;54:51-62 (887-898).
 
16) 深田順一. ストレスとからだ. からだの中からストレスをみる. 東京:学習出版センター ;2000:1-37.
 
17) 下光輝一. 心理社会ストレス-ヒトと環境とのかかわり. 運動とストレス科学 (竹宮 隆, ら編). 2003, p16-33, 東京, 杏林書院.
 
18) Shimomitsu T, Odagiri Y, et al. Endocrinological Assessment of Extreme Stress. Everyday Biological Stress Mcchanisims 2001;22:35-51.
 
19) Wolf TO, Clemens K. Actions of dehydroepiandrosterone and its sulfate in the central nervous system:effects on cognition and emotion in animals and humans. Brain Research Reviews 1999;30:264-288.
 
20) Yukioka M, Komasubara Y, Yukioka K, et al. Adrenocorticotropic hormone and dehydroepiandrosterone sulfatelevels of rheumatoid arthritis patients with glucocorticoids. Mod Rheumatol 2006;16:30-35.
 
21) 西風 脩, 土屋悦子. 尿17-Ketosteroid硫酸抱合体と17-Hydroxycorticosteroidグルクロン酸抱合体. 臨床化学1998;17:55-63.
 
22) 西風 脩. 適応の歪み-摩耗と修復-(17-KS硫酸の意味するもの). JUOEH (産業医科大学雑誌) 1993; 15:183-208.
 
23) 西風 脩. 内分泌学の新展開. Dehydroepiandrosterone 17-KS-Sulfates (17-KS-S) とは. 臨床病理 1998;46:520-528.
Medical*Online
24) 西風 脩, 土屋悦子. Catatoxic Steroidとしての17-KS硫酸全人的医療1998:3:38-44.
 
25) 土屋悦子, 前澤 貢, 西風 脩:心理社会的ストレスと17-KS-S. 臨床病理1998;46:529-537.
 
26) 行岡正雄, 小松原良雄, 七川歓次, ら:尿中ステロイドホルモンを用いたRA患者のストレス測定. 臨床リウマチ2004;16:301-307.
 
27) Sakaguchi T, Nakamura S. Duration-dependent effects of repeated restraint stress on cortical projections of locus coeruleus neurons. Neurosci Lett 1990;118:193-196.
PubMed
28) Simpson R, Hoffman-Goetz L. Exercise stress and murine natural killer cell function. Proc Soc Exp Biol Med 1990;195:129-135.
 
29) Douglas DJ, Hanson PG. Upper respiratory infections in conditioned athlete. Med Sci Sports Exerc 1998;10:55.
 
30) Peters EM, Bateman ED. Ultramarathon running and upper repiratory tract infections. S Afr Med J 1983:64:582-584.
 
31) Fitzgerald L. Exercise and immune system. Immunology Today 1998;9:337-339.
 
32) O'Connor PJ. オーバートレーニングとステイルネス. 身体活動とメンタルヘルス (竹中晃二, ら監訳). 1999, p193-213, 東京, 大修館書店.
 
33) Raglin JS. Overtraining and staleness. Psychometric monitoring of endurance athletes. Singer RB, Murphy M, Tennaut LK. Handbook of Research on Sports Psychology. New York:Macmillan;1993:840-850.
 
34) 川崎彰子, 目崎 登. 運動性ストレスと月経異常. 日本臨床スポーツ医学会誌2006;14. 3:399-407.
 
35) 村瀬訓生, 勝村俊仁. オーバートレーニング症候群. 臨床スポーツ医学2006;23, 8:883-887.
 
36) 太田 眞, 平井徳幸, 小野安雄, ら. 超時間持続的運動における中枢性疲労の生化学的検討 (24時間ランニングの脳疲労). 臨床病理2005;53:803-809.
 
37) Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT ac-tivity during prolonged exercise to fatigue. J Appl Physiol 1993;74:3006-3012.
 
38) 征矢英昭. 運動時の中枢性疲労とアミノ酸代謝-セロトニン仮説を中心に-. 体育の科学1999;49:983-990.
 
39) Davis JM, Alderson LN, Welsh SR. Serotonin and central nervous system fatigue:nutritional consid-erations. Am J Clin Nutr 2000;72:573-578.
 
40) Uusitalo ALT, Valkonen-Korhonen M, Helenius P, et al. Abnormal serotonin reuptake in an overtrained. International journal of sports medicine 2004;25:150-153.
 
41) Agawa H, Yamada N, Enomoto Y, et al. Changes of mental stress biomarkers in ultramarathon. International journal of sports medicine 2008;29:867-871.
PubMed
42) 鈴木映二. セロトニンと精神科治療薬. セロトニンと神経細胞・脳・薬物. 2002, p119-175, 東京, 星和書店.
 
43) 樋口輝彦. 生物学的成因・病態. 臨床精神医学講座4. 気分障害. 1998, p43-60, 東京, 山中書店.
 
44) 征矢英昭, 大岩奈青. アロスタシスからみた運動ストレスと内分泌反応. 運動とストレス科学. 2003, p56-170, 東京, 杏林書院.
 
45) McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998;338:171-179.
PubMed
P.147 掲載の参考文献
1) Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37:1-31.
 
2) Hofmann MA, Lalla E, Lu Y, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001;107:675-683.
 
3) 森田啓行. ホモシステイン. 高脂血症ナビゲーター. 第1版 (山田信博編集). 2003, p100-101, 東京, メディカルレビュー社.
 
4) 鏑木淳一. 血漿総ホモシステイン濃度測定の臨床的意義-人間ドックにおける有用性-. 人間ドック 2007;22:50-54.
 
5) Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. J Am Med Assoc 1997;277:1775-1781.
 
6) Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. New Engl J Med 1997;337:230-236.
PubMed
7) Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-1124.
PubMed
8) Von Feldt JM, Scalzi LV, Cucchiara AJ, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Ar-thritis Rheum 2006;54:2220-2227.
 
9) Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003;349:2407-2415.
PubMed
10) Nazarinia MA, Aflaki E, Habibaghahi Z, et al. Serum homocysteine level and vascular thrombosis in patients with Behcet disease. APLAR J Rheum 2007;10:178-181.
 
11) Homocysteine lowering trialist:collaboration. Homocysteine lowering trialist:collaboration. Lowering blood homocysteine with folic acid based supplements:meta-analysis of randomized trials. Br Med J 1998;316:894-898.
 
12) Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. New Engl J Med 2006;354:1578-1588.
PubMed
13) Doshi SN, McDowell IFW, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-26.
 
14) Yxfeldt A, Wallberg-Jonsson S, Hultdin J, et al. Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol 2003:32:205-210.
 
15) Herrmann M, Schmidt JP, Umanskaya N, et al. The role of hyperhomocysteinemia as well as folate, vitamin B6 and B 12deficiencies in osteoporosis-asystemic review. Clin Chem Lab Med 2007;45:1621-1632.
 
P.154 掲載の参考文献
1) 蔵本由紀. 新しい自然学-非線形科学の可能性. 岩波書店:2003年.
 
2) 吉田善章. 非線形とは何か-複雑系への挑戦-. 岩波書店:2008年.
 
3) Hasegawa A Optical soliton in dielectric fibers and self-organization of turbulence in plasmas in magnetic fields. Proc Jpn Acad Ser 2009;B85:1-11.
 
4) Smyth CJ. Therapy of rheumatoid arthritis. A pyramidal plan. Postgrad Med 1972;51:31-39.
PubMed

治療と副作用

P.159 掲載の参考文献
1) Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-157.
PubMed
2) Karin M, Liu Z-G, Zandi E. AP-1 function and regulation. Cur Opin Cell Biol 1997;9:240-246.
 
3) Angel P, Imagawa M, Chiu R, et al. Phorbol ester inducible genes contain a common cis element recognized by a TPA-modulated transacting factor. Cell 1987;49:729-739.
PubMed
4) Schonthal A, Herrlich P, Rahmsdorf HJ, et al. Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell 1988;54:325-334.
PubMed
5) Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 1990;9:2241-2246.
PubMed
6) Shiozawa S, Tanaka Y, Fujita T, et al. Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. J Immunol 1992;148, 3100-3104.
PubMed
7) Kuroki Y, Shiozawa S, Sugimoto T, et al. Constitutive expression of c-fos gene inhibits type l collagen synthesis in transfected osteoblasts. Biochem Biophys Res Commun 1992;182:1389-1394.
 
8) Miyauchi A, Kuroki Y, Fukase M, et al. Persistent expression of proto-oncogene c-fos stimulates osteoclast differentiation. Biochem Biophys Res Commun l 994;205:1547-1555.
 
9) Shiozawa S, Shimizu S, Tanaka K, et al. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997;99:1210-1216.
 
10) Kawasaki H, Komai K, Ouyang Z, et al. c-Fos/activator protein-1 transactivates wee1 kinase at G1/S to inhibit premature mitosis in antigen-specific Th l cells. EMBO J 2001:20:4618-4627.
 
11) Kawasaki H, Komai K, Nakamura M, et al. Human weel kinase is directly transactivated by and increased in association with c-Fos/AP-1:rheumatoid synovial cells overexpressing these genes go into aberrant mitosis. Oncogene 2003:22:6839-6844.
 
12) Sirum-Connolly K, Brinckerhoff C. Interleukin-10r phorbol induction of the stromelysin promoter requires an element that cooperates with AP-1. Nucleic Acids Res 1991;19:335-341.
 
13) Hess J, Porte D, Munz C, et al. AP-1 and Cbfa/Runt physically interact and regulate parathyroid hormone-dependent MMP 13 expression in osteoblasts through a new osteoblast-specific element 2/ AP-1 composite element. J Biol Chem 2001;276:20029-20038.
 
14) Sun Y, Wenger L, Brinckerhoff CE, et al. Basic calcium phosphate crystals induce matrix metallo-proteinase-1 through the Ras/mitogen-activated protein kinase/c-Fos/AP-1 metalloproteinase l pathway. J Biol Chem 2002;277:1544-1552.
 
15) Milner JM, Patel A, Rowan AD. Emerging roles of serine proteinases in tissue turnover in arthritis. Arthritis Rheum 2008;58:3644-3656.
PubMed
16) Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinase:role in arthritis. Front Biosci 2006; 11:529-543,
PubMed
17) Shiozawa S, Shiozawa K, Fujita T. Morphologic observations in the early phase of the cartilage-pannus junction. Arthritis Rheum 1983;26:472-478.
PubMed
18) Fassbender HG. Is pannus a residue of inflammation? Arthritis Rheum 1984:27:956-957.
 
19) Shiozawa S, Tanaka Y, Fujita T, et al. Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. J Immunol 1992;148:3100-3104.
PubMed
20) Trabandt A, Aicher WK, Gay RE, et al. Spontaneous expression of immediately-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts. Rheumatol Int 1992; 12:53-59.
 
21) Asahara H, Fujisawa K, Kobata T, et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997;40:912-918.
PubMed
22) Aicher WK, Heer AH, Trabandt A, et al. Overexpression of zinc-finger transcription factor Z-225/Egr-1 in synoviocytes from rheumatoid arthritis patients. J Immunol 1994;152:5940-5948.
PubMed
23) Wakisaka S, Suzuki N, Takeno M, et al. Involvement of simultaneous multiple transcription factor expression, including cAMP responsive element binding protein and OCT-1, for synovial cell out-growth in patients with rheumatoid arthritis. Ann Rheum Dis 1998:57:487-497.
 
24) Pope RM, Lovis R, Mungre S, et al. C/EBP beta in rheumatoid arthritis:correlation with inflammation, not disease specificity. Clin Immunol 1999:91:271-282.
 
25) Jacobs RA, Perrett D, Axon JM, et al. Rheumatoid synovial cell proliferation, transformation and fibronectin secretion in culture. Clin Exp Rheumatol 1995:13:717-723.
PubMed
26) Schaser K, Kinne RW, Beil H, et al. Proliferation of T-cells, macrophages, neutrophilic granulocytes and fibroblast-like cells in the synovial membrane of patients with rheumatoid arthritis. Verh Dtsch Ges Pathol 1996;80:276-280.
PubMed
27) Fassbender HG. Joint destruction in various arthritic diseases. In:Kuettner K et al., eds. Articular cartilage biochemistry. New York:Raven Press;1986:371-389.
 
28) Shimizu S, Shiozawa S, Shiozawa K, et al. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 1985;28:25-31.
PubMed
29) Schett G, Stach C, Zwerina J, et al. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2008;58:2936-2948.
PubMed
30) Dayer J-M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003;42 (Suppl. 2):ii3-ii10,
 
31) Van de Loo AAJ, van den Berg WB. Effects of murine recombinant IL-10n synovial joints in mice:measurement of patellar cartilage metabolisrn and joint inflammation. Ann Rheum Dis 1990:49:238-245.
 
32) Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and TNF in the rabbit:evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989;75:306-310.
PubMed
33) Kawasaki Y, Xu Z-Z, Wang X, et al. Distinct roles of matrix metalloproteinases in the early-and late-phase development of neuropathic pain. Nat Med 2008;14:331-336.
PubMed
34) Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine rnessenger RNA expression. Arthritis Rheum 1999;42:1109-1118.
PubMed
35) AikawaY, Morimoto K, Yamamoto T, et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008;26:817-823.
PubMed
36) Van den Berg WB. Lessons from animal models of arthritis. Curr Rheumatol Rep 2002;4:232-239.
PubMed
37) Joosten LAB, Helsen MMA, Saxne T, et al. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF α blockade only ameliorates joint destruction. J Immunol 1999;163:5049-5055.
 
38) Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in IL-1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-320.
PubMed
39) Chikanza IC, Roux-Lombrad P, Dayer JM, Panayi GS. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum 1995;38:64-648.
 
40) Kahle P, Saal JG, Schaudt K, et al. Determination of cytokines in synovial fluids:correlation with diagnosis and histomorphological characteristics of synovial fluid. Ann Rheum Dis 1992;51:731-734.
PubMed
41) Koch AE, Kunkel SL, Chensue SW, et al. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 1992;65:23-29.
PubMed
42) Eastgate JA, Symons JA, Wood NC, et al. Correlation of plasma interlukin-11evels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-708.
 
43) Rooney M, Symons JA, Duff GW. Interlukin-1β in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int 1990;10:217-219.
 
44) Smolen JS, van der Heijde DM, St. Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab:results from ASPIRE trial. Arthritis Rheum 2006;54:702-710.
PubMed
45) Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomized controlled trial. Lancet 2004;363:675-681.
PubMed
46) Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy:arandomized, placebo-conrolled, 52-week trial. Arthritis Rheum 2004;50:1400-1411.
 
47) Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602.
PubMed
48) Weinblatt ME, Keystone EC, Furst ED, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial. Arthritis Rheum 2003;48:35-45.
 
49) Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis α monoclonal antibody, versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomized phase III trial. Lancet 1999;354:1932-1939.
 
50) Tsai EY, Falvo JV, Tsytsykova AV, et al. A lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp 1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo. Mol Cell Biol 2000;20:6084-6094.
 
51) Finnegan A, Doodes PD. Pathways for interleukin-1-driven arthritis. Arthritis Rheum 2008;58:3282-3285.
 
52) Ventura J-J, Kennedy NJ, Lamb JA, et al. c-Jun NH2-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol Cell Biol 2003;23:2871-2882.
 
53) Koenders MI, Devesa I, Marijnissen RJ, et al. Interleukin-1 drives pathogenic Th 17cells during spon-taneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 2008:58:3461-3470.
 
54) Stockinger B, Veldhoen M. Differentiation and function of Th 17Tcells. Curr Opin Immunol 2007; 19:281-286.
 
55) Reunanan N, Li S-P, Ahonen M, et al. Activation of p38α MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 2002;277:32360-32368.
 
56) Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26.
 
57) Ray A, Bal BS, Ray BK. Transcriptional induction of matrix metalloproteinase-9 in the chondrocyte and synoviocyte cells is regulated via a novel mechanism:evidence for functional cooperation between serum amyloid A-activating factor-1 and AP-1. J Immunol 2005;175:4039-4048.
 
58) Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodelling. Nat Med 2007:13:156-163.
PubMed
59) Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th 17 and regulatory T cells. Nature 2006:441:235-238.
PubMed
60) Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-β induces development of the Th 171ineage. Nature 2006;441:231-234.
 
61) Veldhoen M, Hocking RJ, Atkins CJ, et al. TGF β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-189.
 
62) Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17:a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-970.
 
63) Ziolkowska W, Koc A, Luszczykiewicz G, et al. High levels of IL-17in rheumatoid arthritis patients:IL-15 triggers in vitro IL 17 production via cyclosporine A-sensitive mechanism. J Immunol 2000; 164:2832-2838.
 
64) Kotake S, Udagawa N, Takahashi N, et al. IL-17in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-1352.
 
65) Hwang SY and Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheurnatoid arthritis patients. Mol Cell 2005;19:180-184.
 
66) Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005:7:R784-R795.
PubMed
67) Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1 β and TNF-α, by human macrophages. J Immunol 1998:160:3513-3521.
 
68) Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-2603.
PubMed
69) Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-821.
PubMed
70) Chaubaud M, Garnero P, Dayer JM, et al. Contribution of interleukin 17to synovium matrix destruction in rheurnatoid arthritis. Cytokine 2000;12:1092-1099.
 
71) Benderdour M, Tardif G, Pelletier JP, et al. Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation:differential activation of AP-1 members by IL-17and IL-1beta. J Rheumatol 2002;29:1262-1272.
 
72) Koshy PJ, Henderson N, Logan C, et al. Interleukin 17induces cartilage collagen breakdown:novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-713.
PubMed
73) Koenders MI, Joosten LAB, van der Berg WB. Potential new targets in arthritis therapy:interleukin (IL)-17and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006;3:iii29-iii33.
 
74) Van Bezooijen RL, van der Wee-Pals L, et al. Interleukin-17synergises with tumour necrosis factor α to induce cartilage breakdown in vitro and in vivo. Ann Rheum Dis 2002:61:870-876.
 
75) Nakae S, Saijo S, Horai R, et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003;100:5986-5990.
PubMed
76) Lubberts E, Koenders MJ, Oppers-Walgreen B, et al. Treatment with a neutralizing antimurine interleukin-17antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004:50:650-659.
 
77) Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th 17responses. Arthritis Rheum 2008;58:3710-3719.
PubMed
78) Horai R, Nakajima A, Habiro K, et al. TNF-α is crucial for the development fo autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004;114:1603-1611.
 
79) Finnegan A, Grusby MJ, Kaplan CD, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002;169:3345-3352.
PubMed
80) Doodes PD, Cao Y, Hamel KM, et al. Development of proteoglycan-induced arthritis is independerlt of IL-17. J Immunol 2008;181:329-337.
PubMed
81) Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005;52:1960-1967.
PubMed
82) Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-l receptor antagonist. Lancet 2004;364:1779-1785.
 
83) Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback 100p via interleukin-6 induction. Immunity 2008;29:628-636.
 
84) Yang E, Lerner L, Besser D, Darnell Jr E. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 2003;278:15794-15799.
PubMed
85) Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, et al. Interleukin-6 modulates production of Tlymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteo-clastogenesis. Arthritis Rheum 2006;54:158-168.
 
86) Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006:54:2817-2829.
PubMed
87) Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI):evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-1167.
 
88) Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study):adouble-blind, placebo-controlled, randomized trial. Lancet 008;371:987-997.
 
89) Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin l receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-1068.
 
90) Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis:radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-1009.
 
91) Zwerina J, Re (llich K, Polzer K, et al. TNF-induced structural joint damage is mediated by interleu-kin-1. Proc Natl Acad Sci USA 2007;104:11742-11747.
 
92) Braddock M, Quinn A. Targeting IL-1 inflammatory disease:new opportunities for therapeutic intervention. Nat Rev Drug Discovery 2004;3:1-10.
PubMed
93) Pap T, Gay S, Schett G. Matrix metalloproteinases. In:Smolen JS, Lipsky PE, editors. Biological therapies in rheumatology. (London):Taylor&Francis Ltd:2002;. P. 483-497.
 
94) Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-2168.
PubMed
95) Van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001;3:18-26.
PubMed
96) Gravallese EM and Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-2151.
PubMed
97) Van de Loo AAJ, van den Berg WB. Effects of murine recombinant IL-10n synovial joints in mice:measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-245.
 
98) Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and TNF in the rabbit:evidence for synergistic interactions between cytokines in vivo. Clin Exp lmmunol 1989;75:306-310.
PubMed
99) Probert T, Plows D, Kontogeorgos G, Kollias G. The type I IL-1 receptor acts in series with TNFα to induce arthritis in TNF α transgenic mice. Eur J Immunol 1995;25:1794-1797.
 
100) Shiozawa S, Shiozawa K, Fujita T. Presence of HLA-DR antigen on synovial type A and B cells:an immunoelectron microscopic study in rheumatoid arthritis, osteoarthritis and normal traumatic joints. Immunology 1983;50:587-594.
 
101) Shimizu S, Shiozawa S, Shiozawa K, Imura S, Ishikawa H, Hirohata K, Fujita T. The restoration of proliferation and differentiation of peripheral blood mononuclear non-adherent cells into immunoglobulinsecreting cells by autologous synovial adherent cells from patients with rheumatoid ar-thritis. Virchow Arch B Cell Pathol 1988;54:350-356.
 
102) Klareskog L, Forsum U, Kabelitz D, et al. Immune functions of human synovial cells:phenotypic and T cell regulatory properties of macrophage-like cells that express HLA-DR. Arthritis Rheum 1982;25:488-501.
 
103) Kuroki Y, Shiozawa S, Yoshihara R, Hotta T. The contribution of human c-fos DNA to cultured synovial cells:atransfection study. J Rhemmatol 1993:20:422-428.
 
104) Shimizu K, Kawasaki H, Morisawa T, et al. Spontaneous and cytokine regulated c-fos gene expression in rheumatoid synovial cells:resistance to cytokine stimulation when the c-fos gene is overex-pressed. Ann Rheum Dis 2000;59:636-640.
 
105) Mudgett JS, Hutchinson NI, Chartrain NA, et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998;41:110-121.
PubMed
106) Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995;269:403-407.
PubMed
107) Scott DL and Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006:355:704-712.
PubMed
108) Teitelbaum SL. RANKing c-Jun in osteoclast development. J Clin Invest 2004;114:463-465.
PubMed
109) Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-mediated joint destruction. J Clin Invest 2002;110:1419-1427.
PubMed
110) Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-286.
PubMed
111) Hashiramoto A, Yamane T, Tsumiyama K, et al. Biological clock modulates arthritis. Subrnitted
 
P.170 掲載の参考文献
1) Langer R, Vacanti JP. Tissue engineering. Science 1993;260:920-926.
PubMed
2) Nishikawa M, Myoui A, Ohgushi H, et al. Bone tissue engineering using novel interconnected porous hydroxyapatite ceramics cornbined with marrow mesenchymal cells:quantitative and three-dimensional image analysis. Cell Transplant 2004;13:367-376.
 
3) Kitoh H, Kitakoji T, Tsuchiya H, et al. Transplantation of culture expanded bone marrow cells and platelet rich plasma in distraction osteogenesis of the long bones. Bone 2007;40:522-528.
 
4) Yamada Y, Ueda M, Hibi H, et al. Translational research for injectable tissue-engineered bone regeneration using mesenchymal stem cells and platelet-rich plasma:From basic research to clinical case study. Cell Transplant 2004;13:343-355.
PubMed
5) 名井 陽, 西川昌孝, 藤本哲穂, ら. 人工骨と間葉系幹細胞を利用した再生医療. 生体医工学 2006;44:530-536.
 
6) Marcacci M, Kon E, Moukhachev V, et al. Stem cells associated with macroporous bioceramics for long bone repair:6-to 7-year outcome of a pilot clinical study. Tissue Eng 2007:13:947-955.
PubMed
7) Vacanti CA, Bonassar LJ, Vacanti MP, et al. Replacement of an avulsed phalanx with tissue-engineered bone. N Engl J Med 2001;344:1511-1514.
 
8) Ohgushi H, Kotobuki N, Funaoka H, et al. Tissue engineered ceramic artificial joint-ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of osteoarthritis. Biomaterials 2005;26:4654-4561.
PubMed
9) Kaito T, Myoui A, Takaoka K, et al. Potentiation of the activity of bone morphogenetic protein-2 in bone regeneration by a PLA-PEG/hydroxyapatite composite. Biomaterials 2005;26:73-79.
PubMed
10) Ogose A, Hotta T, Kawashima H, et al. Comparison of hydroxyapatite and beta tricalcium phosphate as bone substitutes after excision of bone tumors. J Biomed Mater Res B Appl Biomater 2005; 72:94-101.
PubMed
11) Tamai N, Myoui A, Tomita T, et al. Novel hydroxyapatite ceramics with an interconnective porous structure exhibit superior osteoconduction in vivo. J Biomed Mater Res 2001;59:110-117.
 
12) Myoui A:Three-dimensionally engineered hydroxyapatite ceramics with interconnected pores as a bone substitute and tissue engineering scaffold. Biomaterials in Orthopedics. Yaszemski MJ, et al. New York;Marcel Dekker:2003:287-300.
 
13) Sakamoto M, Nakasu M, Matsumoto T, et al. Development of superporous hydroxyapatites and their examination with a culture of primary rat osteoblasts. J Biomed Mater Res A 2007:82:238-242.
PubMed
14) Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
PubMed
15) de Wynter EA, Testa NG. Mesenchymal stem cells:characteristics and potential clinical use. Progress in Growth Factors 2000:6:2-3.
 
16) Phinney DG, Prockop DJ. Concise review:mesenchymal stem/multipotent stromal cells:the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007;25:2896-2902.
PubMed
17) Yoshikawa T, Ohgushi H, Tamai S. Immediate bone forming capability of prefabricated osteogenic hydroxyapatite. J Biomed Mater Res 1996;32:481-492.
PubMed
18) 名井 陽. 骨の再生. 最新整形外科学大系第3巻運動器の治療学 (越智隆弘 編). 2009, p364-369, 東京, 中山書店,
 
P.177 掲載の参考文献
1) Miyasaka N. CHANGE Study Investigators Clinical investigation in highly disease affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation:the CHANGE study. Mod Rheumatol 2008;18:252-62.
 
2) Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody:amulticenter, double-blind, placebo controlled trial. Arthritis Rheum 2004;50:1761-1769.
 
3) Nishirnoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an adequate response to methotrexate (SATORI):significant reduction in disease activity and serum vasucular endothelial growth factor by IL-6 receptor inhibi-tion therapy/Mod Rheumatol?
 
4) Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI):evidence of clinical and radiographic benefit from an x-ray reader-blinded randomaised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-1167.
 
5) Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study):asingle-blind randomized controlled trial. Lancet 2004;364:263-269.
 
6) Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis:10ng-term structural benefits of a brief intervention. Arthritis Rheum 2002:46:347-356,
 
7) Smolen JS, van der Heijde D, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concornitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 2006;54:702-710.
PubMed
8) Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect Of the combination of etanercept and methotraxate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomaised, controlled trial. Lancet 2004:363:675-681.
 
9) Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study:combination therapy with adalimumab plus methotraxate versus methotrxate alone or adalimumab alone in methotrexatenal:ve patients with early, aggressive, rheumatoid arthritis. Arthritis Rheum 2006;54:26-37.
 
10) Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcome of four different treatment strategies in patients with early rheumatoid arthritis (the Best Study). Arthritis Rheum 2005;52:3381-3390.
PubMed
11) Saag RG, TENG GG, PATRAR NH, et al. American College of Rheumatology 2008 recommendations for use of nonbiologic and biologic disease modifying ant-rheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784.
 
P.182 掲載の参考文献
1) Lipsky PE, van der Heijde DM, St Clair EW, et al. Anti-Tumor Necrosis Factor Trial in Rheurnatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602.
 
2) Klareskog L, van der Heijde D, de Jager JP, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthri-tis:double-blind randomised controlled trial. Lancet 2004;363:675-681.
 
3) Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study:Amulticenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
 
4) Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheurnatol 2007;17:28-32.
 
5) Tanaka Y, Takeuchi T, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan:one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 2008;18:146-152.
 
6) Takeuchi T, Yamanaka H, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan:one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol 2008;18:447-454.
 
7) 日本リウマチ学会ホームページ (http://ryumachi-jp.com)
 
8) Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003:30:1426-1435.
PubMed
9) Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody:amulticenter, double-blind, placebo controlled trial. Arthritis Rheum 2004;50:1761-1769.
 
10) Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004:113:1271-1276.
 
11) Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996:11:88-95.
PubMed
12) Udagawa N, Takahashi N, Katagiri T, et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 1995;182:1461-1468.
 
13) Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI):evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007:66:1162-1167.
 
14) Maini RN, Taylor PC, Szechinski J, et al. CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-2829.
 
15) Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals:results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-1523.
PubMed
P.190 掲載の参考文献
1) 国民生活基礎調査 (厚生労働省大臣官房統計情報部編) 1986-2004.
 
2) Wollaston WH. On gouty and urinary concretion. Phil Trans 1797;2:386-400.
 
3) McCarty DJ. Pathogenesis and treatment of the acute attack of gout. Clin Orthop Relat Res 1970; 71:28-39.
PubMed
4) Campion EW, Glym RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med l 987:82:421-426.
 
5) Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27:1501-1505.
 
6) Hall AP, Barry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967;42:27-37.
PubMed
7) Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part I[:Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2006;65:1312-1324.
PubMed
8) 日本痛風・核酸代謝学会. 高尿酸血症, 痛風の治療ガイドライン 第一版. 2002.
 
9) Becker MA, Schumacher HRJr, Wortmann RL, et al. Febuxostat compared with allopurinol in pa-tients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461.
 
10) Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004;23:1117-1118.
PubMed
11) Schumacher HRJr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and pla-cebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week, phase III, random-ized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-1548.
 
12) Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004;23:1119-1122.
PubMed
13) Kamatani N, Fujimori S, Hada T, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia. Arthritis Rheum 2004:50 (Suppl):S337.
 
P.207 掲載の参考文献
1) National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:Sl-S266.
 
2) Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population:the Hisayama Study. Kidney Int 2005;68:228-236.
 
3) Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization hospitalization. N Engl J Med 2004;351:1296-1305.
PubMed
4) Grossfeld GD, Litwin MS, Wolf JS Jr, et al. Evaluation of asymptomatic microscopic hematuria in adults:the American Urological Association best practice policy--part H:patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology 2001; 57:604-610.
 
5) Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69:1264-1271.
PubMed
6) Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-663.
 
7) Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renninangiotensin system and other antihypertensive drugs on renal outcomes:systematic review and meta-analysis. Lancet 2005;366:2026-2033.
 
8) The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349:1787-1792.
 
9) Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
 
10) The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet l 997;349:1857-1863.
 
11) MacKinnon M. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease:asystematic review of the efficacy and safety data. Am J Kidney Dis 2006;48:8-20.
 
12) Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006:354:131-140.
PubMed
13) Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patierlts with type 2 diabetes. Am J Hypertens 2006;19:1241-1248.
 
14) Uzu T, Harada T, Namba T, et al. Thiazide diurctics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 2005;23:861-865.
PubMed
15) 中野正明, 殷 安, 斎藤隆生, ら. 慢性関節リウマチ:合併症と対策-腎合併症. 日本臨床1992;50:576-580.
 
16) Koseki Y, Terai C, Moriguchi M, et al:Aprospective study on renal involvement in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:327-331.
 
17) Nanke Y, Akama H, Terai C, et al. Rapidly progressive glomerulonephritis with D-penicillamine. Am J Med Sci 2000;320:398-402.
PubMed
18) Cheng HF, Harris RC. Cyclooxygenase, the kidney, and hypertension. Hypertension 2004;43:525-530.
PubMed
19) Moriguchi M, Terai C, Koseki Y, et al. Genotypes at SAAI locus correlate with the clinical severity of AA-amyloidosis. Amyloid 2001;8:115-120.
 
20) Nakano M, Ueno M, Nishi S, et al. Anaylysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 1998;50;154-160.
 
21) Moriguchi M, Terai C, Koseki Y, et al. Renal function estimated from serum creatinine is overestimated in patients with rheumatoid arthritis because of their muscle atrophy. Mod Rheum 2000;10:230-234.
 
P.217 掲載の参考文献
1) Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006:354;731-739.
PubMed
2) Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries:a French population-based study. Hepatology 2002:36;451-455.
PubMed
3) Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005:4;489-499.
PubMed
4) Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17tertiary care centers in the United States. Ann Intern Med 2002:137:947-954.
PubMed
5) 三藤留美, 岩佐元雄, 足立幸彦:薬物性肝障害の実態と疫学. 医学のあゆみ2005:214;765-769.
 
6) 池田敏彦:肝機能障害. 日薬理誌2006:127;454-459.
 
7) Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis 2007:11;459-475.
PubMed
8) 厚生労働省:重篤副作用疾患別対応マニュアル薬物性肝障害平成20年4月 (http://www.info.pmda.go.jp/juutoku/juutokuindex.html)
 
9) Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury:an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005:129;512-521. Erratum in:Gastroenterology 2005:129;1808.
 
10) Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepato-toxicity. Crit Rev Toxicol 2005:35;325-361.
 
11) Lucena MI, Garcia-Cortes M, Cueto R, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008:2;141-158. Erratum in:Fundam Clin Pharmacol 2009:23; 147.
 
12) Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006:8:E48-54.
PubMed
13) Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003:349;474-485.
PubMed
14) Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006:10:207-217.
PubMed
15) West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997:23;883-915.
PubMed
16) Bjorkman DJ, Hammond EH, Lee RG, et al. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988:31:1465-1472.
PubMed
17) 中沼安二:肝臓の構造と機能からだの科学2008:258:6-10.
 
18) Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell:its role in human liver disease. Virchows Arch 1997:430;195-207.
PubMed
19) Kremer JM, Alarcon GS, Lightfoot RWJr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology Arthritis Rheum 1994:37;316-328.
PubMed
20) Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis:clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006:73;388-395.
PubMed
21) Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthri-tis Rheum 1989:32:121-127.
 
22) Kremer JM, Furst DE, Weinblatt ME, et al. Significant changes in serum AST across hepatic histological biopsy grades:prospective analysis of 3 cohorts receiving methotrexate therapy for rheuma-toid arthritis. J Rheumatol 1996:23;459-46.
 
23) Kremer JM, Kaye GI, Kaye NW, et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995:38;1194-1203.
PubMed
24) Kremer JM. Not yet time to change the guidelines for monitoring methotrexate liver toxicity:they have served us well. J Rheumatol 2002:29;1590-1592.
 
25) Ros S, Juanola X, Condom E, et al. Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand J Rheumatol 2002:31;330-6.
PubMed
26) Erickson AR, Reddy V, Vogelgesang SA, et al. Usefulness of the American College of Rheumatol-ogy recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthri-tis Rheum 1995:38;1115-1119.
 
27) Fathi NH, Mitros F, Hoffman:J, et al. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3. 5year double blind study in rheumatoid arthritis. J Rheumatol 2002:29;2092-2098.
 
28) Yazici Y, Sokka T, Kautiainen H, et al, Long term safety of methotrexate in routine clinical care:discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005:64:207-211.
PubMed
29) Clegg DO, Furst DE, Tolman KG, et al. Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis. J Rheumatol 1989:16:1123-1126.
PubMed
30) Phillips CA, Cera PJ, Mangan TF, et al. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992:19;229-233.
 
31) Ting TV, Hashkes PJ. Methotrexate/naproxen-associated severe hepatitis in a child with juvenile idiopathic arthritis. Clin Exp Rheurnatol 2007:25:928-929.
 
32) Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheurn 1993:36:329-335.
PubMed
33) Keystone E, Haraoui B. Disease-modifying antirheumatic drugs 4:leflunomide. In Rheumatology (Hochberg MC, Silman AJ, Smolen JS, et al, eds), Spain, Mosby, 2007:461-469.
 
34) Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy:open-label extension of arandomized, double-blind, placebo controlled trial. J Rheumatol 2004:31;1521-1531.
 
35) Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 2000:43;2609-2611.
 
36) Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis:Acase series from a local surveillance of serious adverse events. BMC Musculo-skelet Disord 2008:9;48.
 
37) http://rheumatology.rg/publications/hotline/0803chf.asp?aud=mem
 
38) Tobon GJ, Cafias C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol 2007:26:578-581.
 
39) Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004:117:87-92.
PubMed
P.232 掲載の参考文献
1) 奥 和美. 慢性関節リウマチにおける薬剤性肺罹患. リウマチ病セミナ-III (七川歡次監修). 1992, p207-217, 大阪, 永井書店.
 
2) Homma S, Kawabata M, Kishi K, et al. Diffuse panbronchiolitis in rheumatoid arthritis. Eur Respir J 1998;12:444-452.
PubMed
3) Yousem SA, Colby TV, Carrington CB. Follicularbronchitis/bronchiolitis. Hum Pathol 1985:16:700-706.
PubMed
4) Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis:incidence trends and risk factors over 46 years. Ann Rheum Dis 2003;62:722-727.
PubMed
5) Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid ar-thritis. J Rheumatol 1994;21:33-36.
 
6) Katzenstein ALA, Fiorelli RF. Non-specific interstitial pneumonia/fibrosis:histologic patterns and clinical significance. Am J Surg Pathol 1994;18:136-147.
 
7) Lee HK, Kirn DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005:127:2019.
 
8) Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases. CT findings Radiology 2004;232:81-91.
PubMed
9) 武村民子. 関節リウマチにおける肺病変の病理像. 日胸2007;66:470-484.
 
10) Mueller-Mang C, Grosse C, Schmid K, et al What Every Radiologist Should Know about Idiopathic Interstitial Pneumonias. Radiographics 2007;27:595-615.
PubMed
11) 小橋陽一郎, 弓場吉哲, 本庄原他. 特発性間質性肺炎の臨床基本病理像IPF/UIP. 日本胸部臨床2003;62 (11月増刊):S69-S74.
 
12) 中山智子, 福田 悠, ら. 薬剤性肺炎の病理組織像. 分子呼吸器病学2004;8:470-475.
 
13) Meyers JL. Pathology of drug-induced lung disorders. In:Katzenstein and Askin:s surgical pathology of non-neoplastic lung disease 3rd ed, Katzenstein AA, ed, Philadelphia:Saunders:1997:81-111.
 
14) Rossi SE, et al. Pulmonary drug toxicity:radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259.
PubMed
15) Flieder DB, et al. Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004;25:37-45.
PubMed
16) Bongartz T, Sutton AJ, Sweeting MJ. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies:systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
PubMed
17) Listing J, Strangfeld A, Kary S. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-3412.
PubMed
18) Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-1133.
PubMed
19) Hoffman OA, Standing JE, Limper AH. Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-mediated mechanism. J Immunol 1993; 150:3932-3940.
PubMed
20) Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992;60:1279-1284.
PubMed
21) Tokuda H, Sakai F, Yamada H. Clinical and Radiological Features of Pneumocystis Pneumonia in Patients with Rheumatoid Arthritis, in comparison with Methotrexate Pneumonitis and Pneumocystis Pneumonia in Acquired Immunodeficiency Syndrome:AMulticenter Study. Inter Med 2008:47:915-923.
 
22) Personal communication
 
23) Yamada T, Nakajima A, InoueE, et al. Increased risk of tuberculosis in patients wlth rheumatoid arthritis in Japan. Ann Rheum Dis 2006;65:166H663.
 

手術

P.247 掲載の参考文献
1) Sauve L, Kapandji M. Nouvelle techunique de traitement chirurgical des luxations recidivarts isolees de lextremite imferieure du cubitus. J Chirurgie 1936:45:589-594.
 
2) 藤田 悟, 政田和洋, 富士武史, ら. 慢性関節リウマチに対するmodified Sauve-Kapandji法. 臨床整形外科1998;33;999-1002.
 
3) Fujita S, Masada K, Takeuchi E, et al. Modified Sauve-Kapandji procedure for disorders of the distal radioulnare joint in patients with the rheumatoid arthritis. J BoneJoint Surg 2005;87-A:134-139.
 
4) Papp SR, Athwal GS, Pichore DR. The rheumatoid wrist. J American Academy of Orthopaedic Surgeone 2006;14:65-77.
 
5) Cavaliere CM, Chung KC. A systematc review of total wrist arthroplasty compared With total wrist arthrodesis for rheumatoid arthritis. Plastic Reconstructive Surg 2008;122:813-825.
PubMed
6) Ishikawa H, Murasawa A, Nakazono K. Longe-term follow-up study of radiocalpal arthrodesis for the rheumatoid arthritis. J Hand Surg 2005;30:658-666.
 
7) Rauhaniemi J, Tiusanen H, Sipola E. Total wrist fusion:Astudy of 115patients. J Hand Surg 2005; 30:217-219.
 
8) Toma CD, Machacek P, Bitzan P, et al. Fusion of the wrist in rheumatoid arthritis. J Bone Joint Surg 2007:89-B:1620-1226.
 
P.254 掲載の参考文献
1) 皆川洋至, 阿倍秀一, 山本宣幸, ほか. 腱板断裂肩の疫学. 日本整形外科学会雑誌2006;80:S217.
 
2) 米田 稔:ビデオ:鏡視下腱板修復術の実際. 日本整形外科学会整形外科卒後教育研修用ビデオ (シリーズ II), 1999;No. 33.
 
3) 米田 稔:鏡視下肩腱板縫合術. 整形外科テレビ講演会, 万有製薬本社ビルから配信, 2005. 6. 9.
 
4) 野中伸介, 米田 稔, 山田真一, ら. Double Anchor Footprint Fixation法を用いた鏡視下腱板修復術のMRI評価:Double Row法との比較. 肩関節2009;33:751-755.
 
5) 菅谷啓之, 前田和彦, 加藤敦夫, ほか. 重層固定法による鏡視下腱板修復術の成績-術後腱板修復状態と術後2年の臨床成績-. 肩関節2006;30:489-493.
 
6) Goutallier D, et al. Fatty muscle degeneration in cuff ruptures. Clin Orthop Relat Res 1994;34:78-83.
 
7) Busfield BT, Glousman RE, McGarry MH, et al. A biomechanical comparison of 2 technical variations of double-Row rotator cuff fixation. Am J Sports Med 2008;36:901-906.
PubMed
P.264 掲載の参考文献
1) 鳥畠康充. 腰部脊柱管狭窄と血管疾患. 臨整外2006;41:865-870.
 
2) 大和田哲雄, 大河内敏行, 山本利美雄. PLIFにおける椎間スペーサーの意義, 各種椎間スペーサーの比較より. J MIOS 2005;37:15-21.
 
3) Hosono N, Namekata M, Makino T, et al. Perioperative complications of primary posterior lumbar interbody fusion for nonisthmic spondylolisthesis:analysis of risk factors. J Neurosurg Spine 2008; 9:403-407.
PubMed
4) Taneichi H, Suda K, Kajino T, et al. Unilateral transforaminal lumbar interbody fusion and bilateral anterior-column fixation with two Brantigan I/F cages per level:clinical outcomes during a minimum 2-year follow-up period. J Neurosurg Spine 2006;4:198-205.
 
5) 坂浦博伸, 細野 昇, 清水広太, ら. 胸視下椎間板切除術 (Microendoscopic discectorny) の初期経験-同一術者によるLove法との比較-臨整外2002;37:955-959.
 
6) 高橋啓介. 安全第一. 脊椎脊髄2007;20:5-6.
 
7) Weiner BK, Walker M, Brower RS, et al. Microdecompression for lumbar spinal canal stenosis. Spine 1999:24:2268-2272.
PubMed
8) 生田 光. 腰部脊柱管狭窄症に対する内視鏡下後方除圧術. 脊椎脊髄 2008;21:433-439.
 
9) Wiltse LL, Spencer CW. New use and refinements of the paraspinal approach to the lumbar spine. Spine 1988;13:696-706.
 
10) 矢吹省司, 恩田 啓, 大谷晃司, ら. 腰椎変性疾患に対するグラフ制動術の手術手技と長期成績, 脊椎脊髄 2008;21:471-475.
 
P.277 掲載の参考文献
1) 福田眞輔. 人工椎間板. リウマチ病セミナー XIV (七川歡次監修). 2005, p259-273, 大阪, 永井書店.
 
2) Fairbank J, Pynsent P. The Oswestry disability index. Spine 2000;25:1940-2953.
 
3) Roland M, Fairbank J. The Roland-Morris Disability Questionnaire and The Oswestry Disability Questionnaire. Spine 2000;25:3115-3124.
PubMed
4) Hashimoto H, Komagata M, Nakai O, et al. Discriminative validity and responsiveness of the Oswestry Disability Index among Japanese outpatients with lumbar conditions. Eur Spine J 2006;15:1645-1650.
PubMed
5) Blumenthal S, McAfee PC, Guyer RD, et al. A prospective, randomized, multicenter Food and Drmg Administration Investigational Device Exemptions Study of lumbar total disc replacement with the CHARITE artificial disc versus lumbar fusion. Part I:Evaluation of clinical outcomes. Spine 2005; 30:1565-1575.
 
6) McAfee PC, Cunningham B, Holsapple G, et al. A prospective, randomized, multicenter Food and Drug Administration Investigational Device Exemptions Study of lumbar total disc replacement with the CHARITE artificial disc versus lumbar fusion. Part II:Evaluation of radiographic outcomes and correlation of surgical technique accuracy with clinical outcomes. Spine 2005;30:1576-1583.
 
7) McAfee PC, Cunningham BW, Devine J, et al. Classification of heterotopic ossification (HO) in artificial disk replacement. J Spinal Disord Tech 2003:16:384-389.
 
8) Tortolani PJ, Cunningham BW, M fee PC, et al. Prevalence of heterotopic ossification following total disc replacement. A prospective, randomized study of two hundred and seventy-six patients. J Bone Joint Surg 2007;89-A:82-88.
 
9) Geisler FH, Blumenthal SL, Guyer RD, et al. Neurological complications of lumbar artificial disc re-placement and comparison of clinical results with those related to lumbar arthrodesis in the literature:Results of a multicenter, prospective, randomized investigational device exemption study of Charity intervertebral disc. J Neurosurg 2004;1:143-154.
 
10) Delamarter RB, Bae HW, Pradhan BB. Clinical results of Pro Disc-II lumbar total disc replacement Report from the United States Clinical Trial. Orthop Clin N Am 2005;36:301-313.
 
11) Sasso RC, Foulk DM, Hahn M. Prospective, randomized trial of metalonmetal artificial lumbar disc replacement. Spine 2008;33:123-131.
 
12) Vernon H. The neck disability index:State-of-the-art, 1991-2008. J Manipulative Physiol Ther 2008; 31:491-502.
PubMed
13) Vernon H, Mior V. The neck disability index:Astudy of reliability and validity. J Manipulative Physiol Ther 1991:14:409-415.
 
14) Sasso RC, Smucker JD, Hacker RJ, et al. Artificial disc versus fusion. A prospective, randomized study with 2-year follow-up on 99 patients. Spine 2007;32:2933-2940.
PubMed
15) Coric D, Finger F, Boltes P. Prospective randomized controlled study of the Bryan cervical disc:Early clinical results from a single investigational site. J Neurosurg Spine 2006:4:31-35.
 
16) Mummaneni PV, Burkus JK, Haid RW, et al. Clinical and radiographic analysis of cervical disc ar-throplasty compared with allograft fusion:Arandomized controlled clinical trial. J Neurosurg Spine 2007;6:198-209.
 
17) Bertagnoli R, Yue JJ, Pfeiffer F, et al. Early results after ProDisc-C cervical disc replacement. J Neu-rosurg Spine 2005;2:403-410.
 
18) Nabhan A, Ahlhelm F, Pitzen T, et al. Disc replacement using Pro-Disc C versus fusion:A prospective randomised and controlled radiographic and clinical study. Eur Spine J 2007;16:423-430.
PubMed
19) Mehren C, Suchomel P, Grochulla F, et al. Heterotopic ossification in total cervical artificial disc re-placement. Spine 2006;31:2802-2806.
 
20) Lemaire J, Carrier H, Ali ES, et al. Clinical and radiological outcomes with the Charite artificial disc. A 10-year minimum follow-up. J Spinal Disord Tech 2005;18:353-359.
 
21) David T. Long-term results of one-level lumbar arthroplasty. Minimum 10-year follow-up of the CHARITE Artificial Disc in 106 patients. Spine 2007;32:661-666.
 
22) Ross R, Mirza AH, Norris HE, et al. Survival and clinical outcomes of SB Charite III disc replacement for back pain. J Bone Joint Surg 2007;89-B:785-789.
 
23) Putzier M, Funk JF, Schneider SV, et al. Charite total disc replacement. Clinical and radiographical results after an average follow-up of 17years. Eur Spine J 2006;15:183-195.
 
24) Tropiano P, Huang RC, Girardi FP, et al. Lumbar total disc replacement. Seven to eleven-year follow-up. J Bone Joint Surg 2005;87-A:490-496.
PubMed
25) Sola S, Hebecker R, Knoop M, et al. Bryan cervical disc prosthesis three years follow-up. Eur Spine J 2005;14:38.
 
26) Leung C, Casey AT, Goffin J, et al. Clinical significance of heterotopic ossification in cervical disc replacement:aprospective multicenter clinical trial. Neurosurgery 2005;57:759-763.
 
27) Bartels RHMA, Donk R. Fusion around cervical disc prosthesis:case report. Neurosurgery 2005; 57:E194.
 
28) Orr RD, Postak PD, Rosca M, et al. The current state of cervical and lumbar spinal disc arthroplasty. JBone Joint Surg 2007;89-A (Suppl 3):70-75.
 
29) Mayer HM. Total lumbar disc replacement. J Bone Joint Surg 2005:87-B:1029-1037.
 
30) Freeman BJC, Davenport J. Total disc replacement in the lumbar spine:Asystematic review of the literature. Eur Spine J 2006:15 (suppl 3):S439-S447.
 
31) OR leaders. Artificial intervertebral disc replacement for symptomatic cervical disc disease:What:s the state of evidence? Supplement to OR Manager 2008;24:No. 1.
 
32) Seo M, Choi D. Adjacent segment disease after fusion for cervical spondylosis;Myth or reality? Brit JNeurosurg 2008:22:195-199.
PubMed

書評

最近チェックした商品履歴

Loading...